Timothy Yap, MBBS, PhD, FRCP

Peer-Reviewed Articles

1. Lei G, Mao C, Horbath AD, Yan Y, Cai S, Yao J, Jiang Y, Sun M, Liu X, Cheng J, Xu Z, Lee H, Li Q, Lu Z, Zhuang L, Chen MK, Alapati A, Yap TA, Hung MC, You MJ, Piwnica-Worms H, Gan B. BRCA1-Mediated Dual Regulation of Ferroptosis Exposes a Vulnerability to GPX4 and PARP Co-Inhibition in BRCA1-Deficient Cancers. Cancer Discov 14(8):1476-1495, 2024. PMID: 38552003.
2. Vokes NI, Le X, Yap TA. PIKing up and AKTing on resistance mutations in osimertinib-treated EGFR-mutated NSCLC. Clin Cancer Res None(None):None, 2024. PMID: 39018064.
3. Nakazawa MS, Silverman IM, Rimkunas V, Veloso A, Glodzik D, Johnson A, Ohsumi TK, Patel SR, Conley AP, Roland CL, Soliman PT, Beird HC, Wu CC, Ingram DR, Lazcano R, Song D, Wani KM, Lazar AJ, Yap TA, Wang WL, Livingston JA. Loss of the DNA Repair Gene RNase H2 Identifies a Unique Subset of DDR-Deficient Leiomyosarcomas. Mol Cancer Ther 23(7):1057-1065, 2024. PMID: 38561019.
4. Pilie PG, Giuliani V, Wang WL, McGrail DJ, Bristow CA, Ngoi NYL, Kyewalabye K, Wani KM, Le H, Campbell E, Sanchez NS, Yang D, Gheeya JS, Goswamy RV, Holla V, Shaw KR, Meric-Bernstam F, Liu CY, Ma X, Feng N, Machado AA, Bardenhagen JP, Vellano CP, Marszalek JR, Rajendra E, Piscitello D, Johnson TI, Likhatcheva M, Elinati E, Majithiya J, Neves J, Grinkevich V, Ranzani M, Luzarraga MR, Boursier M, Armstrong L, Geo L, Lillo G, Tse WY, Lazar AJ, Kopetz SE, Geck Do MK, Lively S, Johnson MG, Robinson HMR, Smith GCM, Carroll CL, Di Francesco ME, Jones P, Heffernan TP, Yap TA. Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor Types. Clin Cancer Res 30(10):2121-2139, 2024. PMID: 38416404.
5. Yap TA, Tolcher AW, Plummer R, Mukker JK, Enderlin M, Hicking C, Grombacher T, Locatelli G, Szucs Z, Gounaris I, de Bono JS. First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors. Clin Cancer Res 30(10):2057-2067, 2024. PMID: 38407317.
6. Fontana E, Rosen E, Lee EK, Hojgaard M, Mettu NB, Lheureux S, Carneiro BA, Cote GM, Carter L, Plummer R, Mahalingam D, Fretland AJ, Schonhoft JD, Silverman IM, Wainszelbaum M, Xu Y, Ulanet D, Koehler M, Yap TA. ATR inhibitor, camonsertib, dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study). J Natl Cancer Inst None(None):None, 2024. PMID: 38710487.
7. Rosen E, Yap TA, Lee EK, Hojgaard M, Mettu NB, Lheureux S, Carneiro BA, Plummer R, Fretland AJ, Ulanet D, Xu Y, McDougall R, Koehler M, Fontana E. Development of a Practical Nomogram for Personalized Anemia Management in Patients Treated with Ataxia Telangiectasia and Rad3-related Inhibitor Camonsertib. Clin Cancer Res 30(4):687-694, 2024. PMID: 38078898.
8. Knisely A, Ahmed J, Stephen B, Piha-Paul SA, Karp D, Zarifa A, Fu S, Hong DS, Rodon Ahnert J, Yap TA, Tsimberidou AM, Alshawa A, Dumbrava EE, Yang Y, Song J, Meric-Bernstam F, Jazaeri AA, Naing A. Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies. Cancer 130(3):400-409, 2024. PMID: 37864520.
9. Nowlen CJ, Daniels M, Uzunparmak B, Ileana Dumbrava EE, Yuan Y, Patel KP, Rayes N, Harkenrider J, Wathoo C, Veazie J, Luna KA, Wang W, Horombe C, Javle M, Ahnert JR, Yap TA, Arun B, Lu KH, Meric-Bernstam F. Limited Independent Follow-Up with Germline Testing of Variants Detected in BRCA1 and BRCA2 by Tumor-Only Sequencing. J Immunother Precis Oncol 7(1):7-17, 2024. PMID: 38327755.
10. Surana R, Gonzalez GN, Rogers J, Hong DS, Yap TA, Rodon J, Naing A, Wolff RA, Smaglo BG, Bernstam FM, Subbiah V, Pant S. Utility of Established Prognostic Scoring Systems for Patients with Advanced Pancreatic Adenocarcinoma Enrolled in Immunotherapy-Based Early-Phase Clinical Trials. J Gastrointest Cancer 54(4):1308-1315, 2023. e-Pub 2023. PMID: 37119430.
11. Geng C, Zhang MC, Manyam GC, Vykoukal JV, Fahrmann JF, Peng S, Wu C, Park S, Kondraganti S, Wang D, Robinson BD, Loda M, Barbieri CE, Yap TA, Corn PG, Hanash S, Broom BM, Pilie PG, Thompson TC. SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor-Induced Growth Suppression. Clin Cancer Res 29(21):4464-4478, 2023. e-Pub 2023. PMID: 37581614.
12. DiPeri TP, Evans KW, Raso MG, Zhao M, Rizvi YQ, Zheng X, Wang B, Kirby BP, Kong K, Kahle M, Yap TA, Dumbrava EE, Ajani JA, Fu S, Keyomarsi K, Meric-Bernstam F. Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers. Clin Cancer Res 29(21):4385-4398, 2023. e-Pub 2023. PMID: 37279095.
13. Yap, TA, Heathman, N, Phillips, T, Beaman, J, Tehrani, M. Additive Manufacturing of Polyaryletherketone (PAEK) polymers and their composites. Composites Part B: Engineering 266, 2023. PMID: None.
14. Uzunparmak B, Haymaker C, Raso G, Masciari S, Wang L, Lin H, Gorur A, Kirby B, Cimo AM, Kennon A, Ding Q, Urschel G, Yuan Y, Feng G, Rizvi Y, Hussain A, Zhu C, Kim P, Abbadessa G, Subbiah V, Yap TA, Rodon J, Piha-Paul SA, Meric-Bernstam F, Dumbrava EE. HER2-low expression in patients with advanced or metastatic solid tumors. Ann Oncol 34(11):1035-1046, 2023. e-Pub 2023. PMID: 37619847.
15. Pettitt SJ, Shao N, Zatreanu D, Frankum J, Bajrami I, Brough R, Krastev DB, Roumeliotis TI, Choudhary JS, Lorenz S, Rust A, de Bono JS, Yap TA, Tutt ANJ, Lord CJ. A HUWE1 defect causes PARP inhibitor resistance by modulating the BRCA1-∆11q splice variant. Oncogene 42(36):2701-2709, 2023. e-Pub 2023. PMID: 37491606.
16. Piha-Paul SA, Tseng C, Tran HT, Gao M, Karp DD, Subbiah V, Tsimberidou AM, Kawedia JD, Fu S, Pant S, Yap TA, Morris VK, Kee BK, Blum Murphy M, Lim J, Meric-Bernstam F. A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation. Cancer Chemother Pharmacol 92(2):107-118, 2023. e-Pub 2023. PMID: 37314501.
17. Johnson A, Ng PK, Kahle M, Castillo J, Amador B, Wang Y, Zeng J, Holla V, Vu T, Su F, Kim SH, Conway T, Jiang X, Chen K, Shaw KRM, Yap TA, Rodon J, Mills GB, Meric-Bernstam F. Actionability classification of variants of unknown significance correlates with functional effect. NPJ Precis Oncol 7(1):67, 2023. e-Pub 2023. PMID: 37454202.
18. Foster KI, Shaw KRM, Jin J, Westin SN, Yap TA, Glassman DM, Jazaeri AA, Rauh-Hain JA, Lee S, Fellman BM, Ju Z, Liu Y, Fleming ND, Sood AK. Clinical implications of tumor-based next-generation sequencing in high-grade epithelial ovarian cancer. Cancer 129(11):1672-1680, 2023. e-Pub 2023. PMID: 36930815.
19. Yap TA, Stadler ZK, Stout LA, Schneider BP. Aligning Germline Cancer Predisposition With Tumor-Based Next-Generation Sequencing for Modern Oncology Diagnosis, Interception, and Therapeutic Development. Am Soc Clin Oncol Educ Book 43(None):e390738, 2023. PMID: 37390373.
20. Yap TA, Fontana E, Lee EK, Spigel DR, Hojgaard M, Lheureux S, Mettu NB, Carneiro BA, Carter L, Plummer R, Cote GM, Meric-Bernstam F, O'Connell J, Schonhoft JD, Wainszelbaum M, Fretland AJ, Manley P, Xu Y, Ulanet D, Rimkunas V, Zinda M, Koehler M, Silverman IM, Reis-Filho JS, Rosen E. Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results. Nat Med 29(6):1400-1411, 2023. e-Pub 2023. PMID: 37277454.
21. Carmagnani Pestana R, Moyers JT, Roszik J, Sen S, Hong DS, Naing A, Herzog CE, Fu S, Piha-Paul SA, Rodon J, Yap TA, Karp DD, Tsimberidou AM, Pant S, Zarzour MA, Ratan R, Ravi V, Benjamin RS, Lazar AJ, Wang WL, Daw N, Gill JB, Harrison DJ, Lewis VO, Roland CL, Patel SR, Livingston JA, Somaiah N, Ludwig JA, Conley AP, Hamerschlak N, Gorlick R, Meric-Bernstam F, Subbiah V. Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101). Clin Cancer Res 29(9):1708-1718, 2023. PMID: 37058010.
22. Meric-Bernstam F, Ford JM, O'Dwyer PJ, Shapiro GI, McShane LM, Freidlin B, O'Cearbhaill RE, George S, Glade-Bender J, Lyman GH, Tricoli JV, Patton D, Hamilton SR, Gray RJ, Hawkins DS, Ramineni B, Flaherty KT, Grivas P, Yap TA, Berlin J, Doroshow JH, Harris LN, Moscow JA. National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH). Clin Cancer Res 29(8):1412-1422, 2023. PMID: 36662819.
23. Yap TA, LoRusso PM, Wong DJ, Hu-Lieskovan S, Papadopoulos KP, Holz JB, Grabowska U, Gradinaru C, Leung KM, Marshall S, Reader CS, Russell R, Sainson RCA, Seal CJ, Shepherd CJ, Germaschewski F, Gliddon D, Stern O, Young L, Brewis N, Kayitalire L, Morrow M. A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 Resistance. Clin Cancer Res 29(5):888-898, 2023. PMID: 36342102.
24. Atkins MB, Ascierto PA, Feltquate D, Gulley JL, Johnson DB, Khushalani NI, Sosman J, Yap TA, Kluger H, Sullivan RJ, Tawbi H. Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies. J Immunother Cancer 11(3), 2023. PMID: 36918225.
25. Glassman D, Kim MS, Spradlin M, Badal S, Taki M, Bhattacharya P, Dutta P, Kingsley CV, Foster KI, Animasahun O, Jeon JH, Achreja A, Jayaraman A, Kumar P, Nenwani M, Wuchu F, Bayraktar E, Wu Y, Stur E, Mangala L, Lee S, Yap TA, Westin SN, Eberlin LS, Nagrath D, Sood AK. Exploiting metabolic vulnerabilities after anti-VEGF antibody therapy in ovarian cancer. iScience 26(2):106020, 2023. e-Pub 2023. PMID: 36824283.
26. Son J, Lin HY, Fu S, Biter AB, Dumbrava EE, Karp DD, Naing A, Pant S, Piha-Paul SA, Rodon J, Subbiah V, Tsimberidou AM, Yap TA, Frumovitz MM, Jazaeri AA, Ramirez PT, Westin SN, Yuan Y, Meric-Bernstam F, Hong DS. Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer. J Immunother Precis Oncol 6(1):10-18, 2023. e-Pub 2023. PMID: 36751659.
27. Moyers JT, Pestana RC, Roszik J, Hong DS, Naing A, Fu S, Piha-Paul S, Yap TA, Karp D, Rodon J, Livingston A, Zarzour MA, Ravi V, Patel S, Benjamin RS, Ludwig J, Herzog C, Ratan R, Somaiah N, Conley A, Gorlick R, Meric-Bernstam F, Subbiah V. Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102). Clin Cancer Res 29(2):401-409, 2023. PMID: 36288393.
28. Heathman, N, Koirala, P, Yap, TA, Emami, A, Tehrani, M. In situ consolidation of carbon fiber PAEK via laser-assisted automated fiber placement. Composites Part B: Engineering 249, 2023. PMID: None.
29. Schram AM, Colombo N, Arrowsmith E, Narayan V, Yonemori K, Scambia G, Zelnak A, Bauer TM, Jin N, Ulahannan SV, Colleoni M, Aftimos P, Donoghue MTA, Rosen E, Rudneva VA, Telli ML, Domchek SM, Galsky MD, Hoyle M, Chappey C, Stewart R, Blake-Haskins JA, Yap TA. Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial. JAMA Oncol 9(1):29-39, 2023. PMID: 36394867.
30. Yap TA, Bardia A, Dvorkin M, Galsky MD, Beck JT, Wise DR, Karyakin O, Rubovszky G, Kislov N, Rohrberg K, Joy AA, Telli ML, Schram AM, Conte U, Chappey C, Stewart R, Stypinski D, Michelon E, Cesari R, Konstantinopoulos PA. Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial. JAMA Oncol 9(1):40-50, 2023. PMID: 36394849.
31. Yap TA, Daver N, Mahendra M, Zhang J, Kamiya-Matsuoka C, Meric-Bernstam F, Kantarjian HM, Ravandi F, Collins ME, Francesco MED, Dumbrava EE, Fu S, Gao S, Gay JP, Gera S, Han J, Hong DS, Jabbour EJ, Ju Z, Karp DD, Lodi A, Molina JR, Baran N, Naing A, Ohanian M, Pant S, Pemmaraju N, Bose P, Piha-Paul SA, Rodon J, Salguero C, Sasaki K, Singh AK, Subbiah V, Tsimberidou AM, Xu QA, Yilmaz M, Zhang Q, Li Y, Bristow CA, Bhattacharjee MB, Tiziani S, Heffernan TP, Vellano CP, Jones P, Heijnen CJ, Kavelaars A, Marszalek JR, Konopleva M. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat Med 29(1):115-126, 2023. e-Pub 2023. PMID: 36658425.
32. Salguero C, Valladolid C, Robinson HMR, Smith GCM, Yap TA. Targeting ATR in Cancer Medicine. Cancer Treat Res 186(None):239-283, 2023. PMID: 37978140.
33. Vo HH, Fu S, Hong DS, Karp DD, Piha-Paul S, Subbiah V, Janku F, Naing A, Yap TA, Rodon J, Ajani JA, Cartwright C, Johnson A, Song IW, Beck J, Kahle M, Nogueras-Gonzalez GM, Miller V, Chao C, Vining DJ, Berry DA, Meric-Bernstam F, Tsimberidou AM. Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology. NPJ Precis Oncol 6(1):78, 2022. PMID: 36302890.
34. Bright SJ, Flint DB, Martinus DKJ, Turner BX, Manandhar M, Ben Kacem M, McFadden CH, Yap TA, Shaitelman SF, Sawakuchi GO. Targeted Inhibition of DNA-PKcs, ATM, ATR, PARP, and Rad51 Modulate Response to X Rays and Protons. Radiat Res 198(4):336-346, 2022. PMID: 35939823.
35. Yap TA, Gainor JF, Callahan MK, Falchook GS, Pachynski RK, LoRusso P, Kummar S, Gibney GT, Burris HA, Tykodi SS, Rahma OE, Seiwert TY, Papadopoulos KP, Blum Murphy M, Park H, Hanson A, Hashambhoy-Ramsay Y, McGrath L, Hooper E, Xiao X, Cohen H, Fan M, Felitsky D, Hart C, McComb R, Brown K, Sepahi A, Jimenez J, Zhang W, Baeck J, Laken H, Murray R, Trehu E, Harvey CJ. First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response. Clin Cancer Res 28(17):3695-3708, 2022. PMID: 35511938.
36. Mendoza TR, Hong DS, Peterson CB, Stephen B, Dumbrava E, Pant S, Tsimberidou AM, Yap TA, Sheshadri A, Altan M, George G, Castillo L, Rodriguez E, Gong J, Subbiah V, Janku F, Fu S, Piha-Paul SA, Ahnert JR, Karp DD, Cleeland C, Meric-Bernstam F, Naing A. Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial. Sci Rep 12(1):14367, 2022. PMID: 35999229.
37. Li X, Dowling EK, Yan G, Dereli Z, Bozorgui B, Imanirad P, Elnaggar JH, Luna A, Menter DG, Pilie PG, Yap TA, Kopetz S, Sander C, Korkut A. Precision Combination Therapies Based on Recurrent Oncogenic Coalterations. Cancer Discov 12(6):1542-1559, 2022. PMID: 35412613.
38. Yap TA, Ashok A, Stoll J, Mauer E, Nepomuceno VM, Blackwell KL, Garber JE, Meric-Bernstam F. Prevalence of Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testing Guidelines. JAMA Netw Open 5(5):e2213070, 2022. PMID: 35594047.
39. Thein KZ, Karp DD, Tsimberidou A, Gong J, Sulovic S, Shah J, Milton DR, Hong DS, Janku F, McQuinn L, Stephen BA, Colen R, Carter BW, Yap TA, Piha-Paul SA, Fu S, Meric-Bernstam F, Naing A. Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study. Invest New Drugs 40(2):290-299, 2022. e-Pub 2021. PMID: 34562230.
40. Yap TA, Bessudo A, Hamilton E, Sachdev J, Patel MR, Rodon J, Evilevitch L, Duncan M, Guo W, Kumar S, Lu S, Dezube BJ, Gabrail N. IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin-paclitaxel, with or without bevacizumab in patients with advanced cancer. J Immunother Cancer 10(3):None, 2022. PMID: 35332062.
41. Alhalabi O, Hahn AW, Msaouel P, Meric-Bernstam F, Wilson N, Naing A, Piha-Paul S, Janku F, Pant S, Yap TA, Hong DS, Fu S, Karp D, Beltran K, Campbell E, Le H, Campbell MT, Shah A, Tannir NM, Siefker-Radtke A, Gao J, Roszik J, Subbiah V. Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials. Clin Genitourin Cancer 20(1):e16-e24, 2022. PMID: 34362693.
42. Garmezy B, Gheeya J, Lin HY, Huang Y, Kim T, Jiang X, Thein KZ, Pilie PG, Zeineddine F, Wang W, Shaw KR, Rodon J, Shen JP, Yuan Y, Meric-Bernstam F, Chen K, Yap TA. Clinical and Molecular Characterization of POLE Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers. JCO Precis Oncol 6(None):e2100267, 2022. PMID: 35108036.
43. Kato S, Adashek JJ, Subbiah V, Fu S, Sun M, Nguyen L, Brown EJ, Yap TA, Karp DD, Piha-Paul SA, Hong DS. A phase i study of ixazomib and erlotinib in patients with advanced solid tumors. Invest New Drugs 40(1):99-105, 2022. PMID: 34468905.
44. Dev R, Zhong LL, Zarifa A, Albittar AA, Rubin L, Liu S, Yap TA, Dalal S, Hui D, Karp DD, Tsimberidou AM, Piha-Paul SA, Ahnert JR, Fu S, Meric-Bernstam F, Naing A. Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study. Invest New Drugs 40(1):124-133, 2022. e-Pub 2021. PMID: 34559346.
45. Yap TA, Hamilton E, Bauer T, Dumbrava EE, Jeselsohn R, Enke A, Hurley S, Lin KK, Habeck J, Giordano H, Shapiro GI. Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes. JCO Precis Oncol 6(None):e2100456, 2022. PMID: 35138920.
46. Coleman N, Subbiah V, Pant S, Patel K, Roy-Chowdhuri S, Yedururi S, Johnson A, Yap TA, Rodon J, Shaw K, Meric-Bernstam F. Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibition. NPJ Precis Oncol 5(1):99, 2021. PMID: 34853384.
47. Evans KW, Yuca E, Scott SS, Zhao M, Paez Arango N, Cruz Pico CX, Saridogan T, Shariati M, Class CA, Bristow CA, Vellano CP, Zheng X, Gonzalez-Angulo AM, Su X, Tapia C, Chen K, Akcakanat A, Lim B, Tripathy D, Yap TA, Francesco MED, Draetta GF, Jones P, Heffernan TP, Marszalek JR, Meric-Bernstam F. Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast Cancer. Cancer Res 81(21):5572-5581, 2021. PMID: 34518211.
48. Yap TA, Coleman RL. The Principles and Practice of PARP Inhibitor Therapy. Cancer J 27(6):430-431, 2021. PMID: 34904805.
49. Do KT, Chow LQM, Reckamp K, Sanborn RE, Burris H, Robert F, Camidge DR, Steuer CE, Strickler JH, Weise A, Specht JM, Gutierrez M, Haughney P, Hengel S, Derleth CL, Yap TA. First-In-Human, First-In-Class, Phase I Trial of the Fucosylation Inhibitor SGN-2FF in Patients with Advanced Solid Tumors. Oncologist 26(11):925-e1918, 2021. PMID: 34288257.
50. Yap TA, Krebs MG, Postel-Vinay S, El-Khouiery A, Soria JC, Lopez J, Berges A, Cheung SYA, Irurzun-Arana I, Goldwin A, Felicetti B, Jones GN, Lau A, Frewer P, Pierce AJ, Clack G, Stephens C, Smith SA, Dean E, Hollingsworth SJ. Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study. Clin Cancer Res 27(19):5213-5224, 2021. PMID: 34301752.
51. Tang Z, Pilie PG, Geng C, Manyam GC, Yang G, Park S, Wang D, Peng S, Wu C, Peng G, Yap TA, Corn PG, Broom BM, Thompson TC. ATR Inhibition Induces CDK1-SPOP Signaling and Enhances Anti-PD-L1 Cytotoxicity in Prostate Cancer. Clin Cancer Res 27(17):4898-4909, 2021. e-Pub 2021. PMID: 34168048.
52. Yap TA, Vieito M, Baldini C, Sepúlveda Sánchez JM, Kondo S, Simonelli M, Cosman R, van der Westhuizen A, Atkinson V, Carpentier AF, Löhr M, Redman R, Mason W, Cervantes A, Le Rhun E, Ochsenreither S, Warren L, Zhao Y, Callies S, Estrem ST, Man M, Gandhi L, Avsar E, Melisi D. First-In-Human Phase I Study of a Next-Generation, Oral, Transforming Growth Factor-Beta Receptor 1 (TGF-βR1) Inhibitor, LY3200882 in Patients with Advanced Cancer. Clin Cancer Res 27(24):6666-6676, 2021. PMID: 34548321.
53. Yap TA, Vieito M, Baldini C, Sepúlveda-Sánchez JM, Kondo S, Simonelli M, Cosman R, van der Westhuizen A, Atkinson V, Carpentier AF, Löhr M, Redman R, Mason W, Cervantes A, Le Rhun E, Ochsenreither S, Warren L, Zhao Y, Callies S, Estrem ST, Man M, Gandhi L, Avsar E, Melisi D. First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer. Clin Cancer Res. e-Pub 2021. PMID: 34548321.
54. Sun H, Cao S, Mashl RJ, Mo CK, Zaccaria S, Wendl MC, Davies SR, Bailey MH, Primeau TM, Hoog J, Mudd JL, 2nd DD, Patidar R, Chen L, Wyczalkowski MA, Jayasinghe RG, Rodrigues FM, Terekhanova NV, Li Y, Lim KH, Wang-Gillam A, Van Tine BA, Ma CX, Aft R, Fuh KC, Schwarz JK, Zevallos JP, Puram SV, Dipersio JF, NCI PDXNet Consortium NCI, Davis-Dusenbery B, Ellis MJ, Lewis MT, Davies MA, Herlyn M, Fang B, Roth JA, Welm AL, Welm BE, Meric-Bernstam F, Chen F, Fields RC, Li S, Govindan R, Doroshow JH, Moscow JA, Evrard YA, Chuang JH, Raphael BJ, TA (Collaborator) DLY. Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment. Nature Communications 12(1):5086, 2021. PMID: 34429404.
55. Shapiro GI, Wesolowski R, Devoe C, Lord S, Pollard J, Hendriks BS, Falk M, Diaz-Padilla I, Plummer R, Yap TA. Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours. Br J Cancer 125(4):520-527, 2021. e-Pub 2021. PMID: 34040174.
56. Giuliani V, Miller MA, Liu CY, Hartono SR, Class CA, Bristow CA, Suzuki E, Sanz LA, Gao G, Gay JP, Feng N, Rose JL, Tomihara H, Daniele JR, Peoples MD, Bardenhagen JP, Geck Do MK, Chang QE, Vangamudi B, Vellano C, Ying H, Deem AK, Do KA, Genovese G, Marszalek JR, Kovacs JJ, Kim M, Fleming JB, Guccione E, Viale A, Maitra A, Emilia Di Francesco M, Yap TA, Jones P, Draetta G, Carugo A, Chedin F, Heffernan TP. PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma. Nat Commun 12(1):4626, 2021. PMID: 34330913.
57. Huey RW, George GC, Phillips P, White R, Fu S, Janku F, Karp DD, Naing A, Piha-Paul S, Subbiah V, Tsimberidou AM, Pant S, Yap TA, Rodon J, Meric-Bernstam F, Shih YT, Hong DS. Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials. Oncologist 26(7):588-596, 2021. PMID: 33783054.
58. Hegde A, Jayaprakash P, Couillault CA, Piha-Paul S, Karp D, Rodon J, Pant S, Fu S, Dumbrava EE, Yap TA, Subbiah V, Bhosale P, Coarfa C, Higgins JP, Williams ET, Wilson TF, Lim J, Meric-Bernstam F, Sumner E, Zain H, Nguyen D, Nguyen LM, Rajapakshe K, Curran MA, Hong DS. A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies. Clin Cancer Res 27(11):3050-3060, 2021. PMID: 33771853.
59. Yap TA, Nakagawa K, Fujimoto N, Kuribayashi K, Guren TK, Calabro L, Shapira-Frommer R, Gao B, Kao S, Matos I, Planchard D, Chatterjee A, Jin F, Norwood K, Kindler HL. Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study. Lancet Respir Med 9(6):613-621, 2021. e-Pub 2021. PMID: 33836153.
60. Jiang L, Li R, Yan F, Yap TA, Yuan Y. Shotgun: A Bayesian seamless phase I-II design to accelerate the development of targeted therapies and immunotherapy. Contemp Clin Trials 104(None):106338, 2021. PMID: 33711459.
61. Patnaik A, Yap TA, Chung HC, de Miguel MJ, Bang YJ, Lin CC, Su WC, Italiano A, Chow KH, Szpurka AM, Yu D, Zhao Y, Carlsen M, Schmidt S, Vangerow B, Gandhi L, Xu X, Bendell J. Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial. Clin Cancer Res 27(5):1267-1277, 2021. PMID: 33229456.
62. Yap TA, Siu LL, Calvo E, Lolkema MP, LoRusso PM, Soria J, Plummer R, de Bono JS, Tabernero J, Banerji U. SARS-CoV-2 vaccination and phase 1 cancer clinical trials. Lancet Oncol 22(3):298-301, 2021. PMID: 33571468.
63. Alhalabi O, Hahn AW, Msaouel P, Andreev-Drakhlin AY, Meric-Bernstam F, Naing A, Piha-Paul S, Filip J, Pant S, Yap TA, Hong DS, Fu S, Karp D, Campbell E, Le H, Campbell MT, Shah AY, Tannir NM, Siefker-Radtke AO, Gao J, Roszik J, Subbiah V. Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes. Mol Cancer Res 19(3):395-402, 2021. PMID: 33323389.
64. Park M, Liu S, Yap TA, Yuan Y. Evaluation of Deviation From Planned Cohort Size and Operating Characteristics of Phase 1 Trials. JAMA Netw Open 4(2), 2021. PMID: 33595664.
65. Yap TA, Tan DSP, Terbuch A, Caldwell R, Guo C, Goh BC, Heong V, Haris NRM, Bashir S, Drew Y, Hong DS, Meric-Bernstam F, Wilkinson G, Hreiki J, Wengner AM, Bladt F, Schlicker A, Ludwig M, Zhou Y, Liu L, Bordia S, Plummer R, Lagkadinou E, de Bono JS. First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors. Cancer Discov 11(1):80-91, 2021. PMID: 32988960.
66. Pascual J, Lim JSJ, Macpherson IR, Armstrong AC, Ring A, Okines AFC, Cutts RJ, Herrera-Abreu MT, Garcia-Murillas I, Pearson A, Hrebien S, Gevensleben H, Proszek PZ, Hubank M, Hills M, King J, Parmar M, Prout T, Finneran L, Malia J, Swales KE, Ruddle R, Raynaud FI, Turner A, Hall E, Yap TA, Lopez JS, Turner NC. Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in PIK3CA-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers. Cancer Discov 11(1):92-107, 2021. PMID: 32958578.
67. Abdel-Wahab R, Yap TA, Madison R, Pant S, Cooke M, Wang K, Zhao H, Bekaii-Saab T, Karatas E, Kwong LN, Meric-Bernstam F, Borad M, Javle M. Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer. Sci Rep 10(1):22087, 2020. PMID: 33328484.
68. Collins DC, Sundar R, Constantidinou A, Dolling D, Yap TA, Popat S, O’Brien ME, Banerji U, de Bono JS, Lopez JS, Tunariu N, Minchom A. Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease. BMC Cancer 20(1):1210, 2020. PMID: 33298007.
69. Hahn AW, Alhalabi O, Msaouel P, Meric-Bernstam F, Naing A, Jonasch E, Piha-Paul S, Hong D, Pant S, Yap T, Campbell E, Le H, Tannir NM, Roszik J, Subbiah V. Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials. ESMO Open 5(6):e001073, 2020. PMID: 33229506.
70. Wang L, Yang L, Wang C, Zhao W, Ju Z, Zhang W, Shen J, Peng Y, An C, Luu YT, Song S, Yap TA, Ajani JA, Mills GB, Shen X, Peng G. Inhibition of the ATM/Chk2 axis promotes cGAS/STING signaling in ARID1A-deficient tumors. J Clin Invest 130(11):5951-5966, 2020. PMID: 33016929.
71. Mendoza T, Sheshadri A, Altan M, Hess K, George G, Stephen B, Castillo L, Rodriguez E, Gong J, Peterson C, Rodon Ahnert J, Fu S, Piha-Paul SA, Pant S, Dumbrava E, Yap TA, Jankku F, Tsimberisou AM, Subbiah V, Karp DD, Zarifa A, McQuinn LM, Cleeland C, Hong DS, Naing A. Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory. J Immunother Cancer 8(2):e000931, 2020. PMID: 33097611.
72. Pettitt SJ, Frankum JR, Punta M, Lise S, Alexander J, Chen Y, Yap TA, Haider S, Tutt ANJ, Lord CJ. Clinical BRCA1/2 Reversion Analysis Identifies Hotspot Mutations and Predicted Neoantigens Associated with Therapy Resistance. Cancer Discov 10(10):1475-1488, 2020. e-Pub 2020. PMID: 32699032.
73. Yap TA, Kristeleit R, Michalarea V, Pettitt SJ Lim JSJ, Carreira S, Roda D, Miller R, Riisnaes R, Miranda S, Figueiredo I, Rodriguez DN, Ward S, Mattews R, Parmar M, Turner A, Tunariu N, Chopra N, Gevensleben H, Turner NC, Ruddle R, Raynaud FI, Decordova S, Swales KE, Finneran L, Hall E, Rugman P, Lindemann JPO, Fozley A, Lord CJ, Banerji U, Plummer R, Basu B, Lopez JS, Drew Y, de Bono JS. Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non- BRCA1/2-Mutant Cancers. Cancer Discov 10(10):1528-1543, 2020. PMID: 3253274.
74. Yap TA, O'Carrigan B, Penney MS, Lim JS, Brown JS, de Miguel Luken MJ, Tunariu N, Perez-Lopez R, Rodrigues DN, Riisnaes R, Figueiredo I, Carreira S, Hare B, McDermott K, Khalique S, Williamson CT, Natrajan R, Pettitt SJ, Lord CJ, Banerji U, Pollard J, Lopez J, de Bono JS. Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors. J Clin Oncol 38(27):3195-3204, 2020. PMID: 32568634.
75. Frumovitz M, Westin SN, Salvo G, Zarifa A, Xu M, Yap TA, Rodon AJ, Karp DD, Abonofal A, Jazaeri AA, Naing A. Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract. Gynecol Oncol 158(3):570-575, 2020. PMID: 32534809.
76. Middleton G, Fletcher P, Popat S, Savage J, Summers Y, Greystoke A, Gilligan D, Cave J, O’Rourke N, Brewster A, Toy E, Spicer J, Jain P, Dangoor A, Mackean M, Forster M, Farley A, Wherton D, Mehmi M, Sharpe R, Mills TC, Cerone MA, Yap TA, Watkins TBK, Lim E, Swanton C, Billingham L. Publisher Correction: The National Lung Matrix Trial of personalized therapy in lung cancer. Nature 585(7826):E21, 2020. PMID: 32887973.
77. Middleton G, Fletcher P, Popat S, Savage J, Summers Y, Greystoke A, Gilligan D, Cave J, O'Rourke N, Brewster A, Toy E, Spicer J, Jain P, Dangoor A, Mackean M, Forster M, Farley A, Wherton D, Mehmi M, Sharpe R, Mills TC, Cerone MA, Yap TA, Watkins TBK, Lim E, Swanton C, Billingham L. The National Lung Matrix Trial of personalized therapy in lung cancer. Nature 583(7818):807-812, 2020. PMID: 32669708.
78. Yap TA, Kristeleit R, Michaelarea V, Pettitt SJ, Lim JSJ, Carreira S, Roda D, Miller R, Riisnaes R, Miranda S, Figueiredo I, Nava Rodrigues D, Ward S, Matthews R, Parmar M, Turner A, Tunariu N, Chopra N, Gevensleben H, Turner NC, Ruddle R, Raynaud FI, Decordova SA, Swales KE, Finneran L, Hall E, Rugman P, Lindemann JPO, Foxley A, Lord CJ, Banerji U, Plummer R, Basu B, Lopez JS, Drew Y, de Bono JS. Phase I trial of the poly(ADP-ribose)Timothy A. Yap, MBBS, PhD, FRCP Page 17 of 46 polymerase (PARP) inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1/2 and non-BRCA1/2 mutant cancers. Cancer Discovery, 2020. PMID: None.
79. Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Rodon Ahnert J, Piha-Paul SA, Colen RR, Jimenez C, Raghav KP, Ferrarotto R, Tu SM, Campbell M, Wang L, Sabir SH, Tapia C, Bernatchez C, Frumovitz M, Tannir N, Ravi V, Khan S, Painter JM, Abonofal A, Gong J, Alshawa A, McQuinn LM, Xu M, Ahmed S, Subbiah V, Hong DS, Pant S, Yap TA, Tsimberidou AM, Dumbrava EEI, Janku F, Fu S, Simon RM, Hess KR, Varadhachary GR, Habra MA. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer 8(1):None, 2020. PMID: 32188704.
80. Yap TA, Winter JN, Giulino-Roth L, Longley J, Lopez J, Michot JM, Leonard JP, Ribrag V, McCabe MT, Creasy CL, Stern M, Pene Dumitrescu T, Wang X, Frey S, Carver J, Horner T, Oh C, Khaled A, Dhar A, Johnson PWM. Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors. Clin Cancer Res 25(24):7331-7339, 2019. e-Pub 2019. PMID: 31471312.
81. Pant S, Maitra A, Yap TA. PARP inhibition - opportunities in pancreatic cancer. Nat Rev Clin Oncol 16(10):595-596, 2019. PMID: 31332344.
82. Fang Y, McGrail DJ, Sun C, Labrie M, Chen X, Zhang D, Ju Z, Vellano CP, Lu Y, Li Y, Jeong KJ, Ding Z, Liang J, Wang SW, Dai H, Lee S, Sahni N, Mercado-Uribe I, Kim TB, Chen K, Lin SY, Peng G, Westin SN, Liu J, O'Connor MJ, Yap TA, Mills GB. Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy. Cancer Cell 35(6):851-867.e7, 2019. PMID: 31185210.
83. Hobbs BP, Barata PC, Kanjanapan Y, Paller CJ, Perlmutter J, Pond GR, Prowell TM, Rubin EH, Seymour LK, Wages NA, Yap TA, Feltquate D, Garrett-Mayer E, Grossman W, Hong DS, Ivy SP, Siu LL, Reeves SA, Rosner GL. Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology. J Natl Cancer Inst 111(2):118-128, 2019. e-Pub 2018. PMID: 30561713.
84. Shen J, Zhao W, Ju Z, Wang L, Peng Y, Labrie M, Yap TA, Mills GB, Peng G. PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness. Cancer Res 79(2):311-319, 2019. e-Pub 2018. PMID: 30482774.
85. O'Brien MER, Sarker D, Bhosle J, Thillai K, Yap TA, Uttenreuther-Fischer M, Pemberton K, Jin X, Wiebe S, de Bono J, Spicer J. A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol 82(5):757-766, 2018. e-Pub 2018. PMID: 30088048.
86. O'Carrigan B, Lim JSJ, Jalil A, Harris SJ, Papadatos-Pastos D, Banerji U, Lopez J, de Bono JS, Yap TA. Target-based therapeutic matching of phase I trials in patients with metastatic breast cancer in a tertiary referral centre. Br J Cancer 119(8):922-927, 2018. e-Pub 2018. PMID: 30318518.
87. Al-Saffar NMS, Troy H, Wong Te Fong AC, Paravati R, Jackson LE, Gowan S, Boult JKR, Robinson SP, Eccles SA, Yap TA, Leach MO, Chung YL. Metabolic biomarkers of response to the AKT inhibitor MK-2206 in pre-clinical models of human colorectal and prostate carcinoma. Br J Cancer 119(9):1118-1128, 2018. e-Pub 2018. PMID: 30377337.
88. Tang C, Jiang W, Yap TA. Efficacy and Toxic Effects of Cancer Immunotherapy Combinations-A Double-edged Sword. JAMA Oncol 4(8):1116-1117, 2018. e-Pub 2018. PMID: 29327039.
89. Vishwanathan K, Dickinson PA, Bui K, Cassier PA, Greystoke A, Lisbon E, Moreno V, So K, Thomas K, Weilert D, Yap TA, Plummer R. The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non-Small-Cell Lung Cancer and in Healthy Volunteers. J Clin Pharmacol 58(4):474-484, 2018. e-Pub 2017. PMID: 29178442.
90. Sun C, Yin J, Fang Y, Chen J, Jeong KJ, Chen X, Vellano CP, Ju Z, Zhao W, Zhang D, Lu Y, Meric-Bernstam F, Yap TA, Hattersley M, O'Connor MJ, Chen H, Fawell S, Lin SY, Peng G, Mills GB. BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency. Cancer Cell 33(3):401-416.e8, 2018. PMID: 29533782.
91. Pilie PG, LoRusso PM, Yap TA. Precision Medicine: Progress, Pitfalls, and Promises. Mol Cancer Ther 16(12):2641-2644, 2017. PMID: 29203693.
92. Yap TA, Rodon J. Development of Molecularly Driven Targeted Combination Strategies. Oncologist 22(12):1421-1423, 2017. e-Pub 2017. PMID: 29038233.
93. Perez-Lopez R, Roda D, Jimenez B, Brown J, Mateo J, Carreira S, Lopez J, Banerji U, Molife LR, Koh DM, Kaye SB, de Bono JS, Tunariu N, Yap TA. High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy. Oncotarget 8(61):104430-104443, 2017. e-Pub 2017. PMID: 29262651.
94. Evans KW, Yuca E, Akcakanat A, Scott SM, Arango NP, Zheng X, Chen K, Tapia C, Tarco E, Eterovic AK, Black DM, Litton JK, Yap TA, Tripathy D, Mills GB, Meric-Bernstam F. A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors. Clin Cancer Res 23(21):6468-6477, 2017. PMID: 29093017.
95. Capelan M, Roda D, Geuna E, Rihawi K, Bodla S, Kaye SB, Bhosle J, Banerji U, O'Brien M, de Bono JS, Popat S, Yap TA. Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?. Lung Cancer 111(None):6-11, 2017. e-Pub 2017. PMID: 28838399.
96. Winfield JM, Tunariu N, Rata M, Miyazaki K, Jerome NP, Germuska M, Blackledge MD, Collins DJ, de Bono JS, Yap TA, deSouza NM, Doran SJ, Koh DM, Leach MO, Messiou C, Orton MR. Extracranial Soft-Tissue Tumors: Repeatability of Apparent Diffusion Coefficient Estimates from Diffusion-weighted MR Imaging. Radiology 284(1):88-99, 2017. e-Pub 2017. PMID: 28301311.
97. Sundar R, Hong DS, Kopetz S, Yap TA. Targeting BRAF-Mutant Colorectal Cancer: Progress in Combination Strategies. Cancer Discov 7(6):558-560, 2017. PMID: 28576843.
98. George A, Kristeleit R, Rafii S, Michie CO, Bowen R, Michalarea V, van Hagen T, Wong M, Rallis G, Molife LR, Lopez J, Banerji U, Banerjee SN, Gore ME, de Bono JS, Kaye SB, Yap TA. Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials. Eur J Cancer 76(None):52-59, 2017. e-Pub 2017. PMID: 28273485.
99. Lim JSJ, Janku F, Yap TA. Circulating tumor DNA-From bench to bedside. Curr Probl Cancer 41(3):212-221, 2017. e-Pub 2017. PMID: 28416241.
100. Papadatos-Pastos D, Roda D, De Miguel Luken MJ, Petruckevitch A, Jalil A, Capelan M, Michalarea V, Lima J, Diamantis N, Bhosle J, Molife LR, Banerji U, de Bono JS, Popat S, O'Brien MER, Yap TA. Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit. Eur J Cancer 75(None):56-62, 2017. e-Pub 2017. PMID: 28214659.
101. Saeed R, Gourley C, Rajiv K, Geuna E, Ang JE, Rye T, Chen L, Shapira-Frommer R, Friedlanders M, Matulonis U, De Greve J, Oza AM, Banerjee S, Molife LR, Gore ME, Kaye SB, Yap TA. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer. Oncotarget. e-Pub 2017. PMID: None.
102. Sundar R, Valeri N, Harrington KJ, Yap TA. Combining Molecularly Targeted Agents: Is More Always Better?. Clin Cancer Res 23(5):1123-1125, 2017. e-Pub 2016. PMID: 27836864.
103. Minchom A, Thavasu P, Ahmad Z, Stewart A, Georgiou A, O'Brien MER, Popat S, Bhosle J, Yap TA, de Bono J, Banerji U. A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments. PLoS One 12(10):e0186106, 2017. e-Pub 2017. PMID: 28982179.
104. Dolly SO, Kalaitzaki E, Puglisi M, Stimpson S, Hanwell J, Fandos SS, Stapleton S, Ansari T, Peckitt C, Kaye S, Lopez J, Yap TA, van der Graaf W, de Bono J, Banerji U. A study of motivations and expectations of patients seen in phase 1 oncology clinics. Cancer 122(22):3501-3508, 2016. e-Pub 2016. PMID: 27716902.
105. Harris SJ, Brown J, Lopez J, Yap TA. Immuno-oncology combinations: raising the tail of the survival curve. Cancer Biol Med 13(2):171-93, 2016. PMID: 27458526.
106. Yap TA, Gillespie L, Ellison S, Flechas SV, Koo MS, Martinez AE, Vredenburg VT. Invasion of the Fungal Pathogen Batrachochytrium dendrobatidis on California Islands. Ecohealth 13(1):145-50, 2016. e-Pub 2015. PMID: 26493624.
107. Khan KH, Yap TA, Ring A, Molife LR, Bodla S, Thomas K, Zivi A, Smith A, Judson I, Banerji U, de Bono JS, Kaye SB. Phase I trial outcomes in older patients with advanced solid tumours. Br J Cancer 114(3):262-8, 2016. e-Pub 2016. PMID: 26757260.
108. Kumar R, Lu SK, Minchom A, Sharp A, Davidson M, Gunapala R, Yap TA, Bhosle J, Popat S, O'Brien ME. A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients. Cancer Chemother Pharmacol 77(2):375-83, 2016. e-Pub 2015. PMID: 26706729.
109. Puglisi M, Stewart A, Thavasu P, Frow M, Carreira S, Minchom A, Punwani R, Bhosle J, Popat S, Ratoff J, de Bono J, Yap TA, O''Brien M, Banerji U. Characterisation of the Phosphatidylinositol 3-Kinase Pathway in Non-Small Cell Lung Cancer Cells Isolated from Pleural Effusions. Oncology 90(5):280-8, 2016. e-Pub 2016. PMID: 27082424.
110. Geuna E, Roda D, Rafii S, Jimenez B, Capelan M, Rihawi K, Montemurro F, Yap TA, Kaye SB, De Bono JS, Molife LR, Banerji U. Complications of hyperglycaemia with PI3K-AKT-mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials. Br J Cancer 113(11):1541-7, 2015. e-Pub 2015. PMID: 26554652.
111. Abdelraouf F, Sharp A, Maurya M, Mair D, Wotherspoon A, Leary A, Gonzalez de Castro D, Bhosle J, Nassef A, Gaafar T, Popat S, Yap TA, O'Brien M. Focused molecular analysis of small cell lung cancer: feasibility in routine clinical practice. BMC Res Notes 8:688, 2015. e-Pub 2015. PMID: 26581482.
112. Frenel JS, Carreira S, Goodall J, Roda D, Perez-Lopez R, Tunariu N, Riisnaes R, Miranda S, Figueiredo I, Nava-Rodrigues D, Smith A, Leux C, Garcia-Murillas I, Ferraldeschi R, Lorente D, Mateo J, Ong M, Yap TA, Banerji U, Gasi Tandefelt D, Turner N, Attard G, de Bono JS. Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration. Clin Cancer Res 21(20):4586-96, 2015. e-Pub 2015. PMID: 26085511.
113. Yap TA, Koo MS, Ambrose RF, Wake DB, Vredenburg VT. BIODIVERSITY. Averting a North American biodiversity crisis. Science 349(6247):481-2, 2015. PMID: 26228132.
114. Rafii S, Roda D, Geuna E, Jimenez B, Rihawi K, Capelan M, Yap TA, Molife LR, Kaye SB, de Bono JS, Banerji U. Higher Risk of Infections with PI3K-AKT-mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials. Clin Cancer Res 21(8):1869-76, 2015. e-Pub 2015. PMID: 25649020.
115. Tolcher AW, Khan K, Ong M, Banerji U, Papadimitrakopoulou V, Gandara DR, Patnaik A, Baird RD, Olmos D, Garrett CR, Skolnik JM, Rubin EH, Smith PD, Huang P, Learoyd M, Shannon KA, Morosky A, Tetteh E, Jou YM, Papadopoulos KP, Moreno V, Kaiser B, Yap TA, Yan L, de Bono JS. Antitumor activity in RAS-driven tumors by blocking AKT and MEK. Clin Cancer Res 21(4):739-48, 2015. e-Pub 2014. PMID: 25516890.
116. Yap TA. Challenges in combining novel molecularly targeted agents in cancer medicine. Ann Oncol 26(1):9-11, 2015. e-Pub 2014. PMID: 25336115.
117. Papadatos-Pastos D, De Miguel Luken MJ, Yap TA. Combining targeted therapeutics in the era of precision medicine. Br J Cancer 112(1):1-3, 2015. PMID: 25562565.
118. Yap TA, Yan L, Patnaik A, Tunariu N, Biondo A, Fearen I, Papadopoulos KP, Olmos D, Baird R, Delgado L, Tetteh E, Beckman RA, Lupinacci L, Riisnaes R, Decordova S, Heaton SP, Swales K, deSouza NM, Leach MO, Garrett MD, Sullivan DM, de Bono JS, Tolcher AW. Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers. Clin Cancer Res 20(22):5672-85, 2014. e-Pub 2014. PMID: 25239610.
119. Ong M, Carreira S, Goodall J, Mateo J, Figueiredo I, Rodrigues DN, Perkins G, Seed G, Yap TA. Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail. Br J Cancer 111(5):828-36, 2014. e-Pub 2014. PMID: 24983367.
120. Ang JE, Gourley C, Powell CB, High H, Shapira-Frommer R, Castonguay V, De Greve J, Atkinson T, Yap TA, Sandhu S, Banerjee S, Chen LM, Friedlander ML, Kaufman B, Oza AM, Matulonis U, Barber LJ, Kozarewa I, Fenwick K, Assiotis I, Campbell J, Chen L, de Bono JS, Gore ME, Lord CJ, Ashworth A, Kaye SB. Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study. Clin Cancer Res 19(19):5485-93, 2013. e-Pub 2013. PMID: 23922302.
121. Sandhu SK, Omlin A, Hylands L, Miranda S, Barber LJ, Riisnaes R, Reid AH, Attard G, Chen L, Kozarewa I, Gevensleben H, Campbell J, Fenwick K, Assiotis I, Olmos D, Yap TA, Fong P, Tunariu N, Koh D, Molife LR, Kaye S, Lord CJ, Ashworth A, de Bono J. Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer. Ann Oncol 24(5):1416-8, 2013. e-Pub 2013. PMID: 23524863.
122. Tan DS, Yap TA, Hutka M, Roxburgh P, Ang J, Banerjee S, Grzybowska E, Gourley C, Gore ME, Kaye SB. Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancer. Eur J Cancer 49(6):1246-53, 2013. e-Pub 2012. PMID: 23265709.
123. Yap TA, Arkenau HT, Camidge DR, George S, Serkova NJ, Gwyther SJ, Spratlin JL, Lal R, Spicer J, Desouza NM, Leach MO, Chick J, Poondru S, Boinpally R, Gedrich R, Brock K, Stephens A, Eckhardt SG, Kaye SB, Demetri G, Scurr M. First-in-human phase I trial of two schedules of OSI-930, a novel multikinase inhibitor, incorporating translational proof-of-mechanism studies. Clin Cancer Res 19(4):909-19, 2013. e-Pub 2013. PMID: 23403628.
124. Yap TA, Walton MI, Grimshaw KM, Te Poele RH, Eve PD, Valenti MR, de Haven Brandon AK, Martins V, Zetterlund A, Heaton SP, Heinzmann K, Jones PS, Feltell RE, Reule M, Woodhead SJ, Davies TG, Lyons JF, Raynaud FI, Eccles SA, Workman P, Thompson NT, Garrett MD. AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity. Clin Cancer Res 18(14):3912-23, 2012. e-Pub 2012. PMID: 22781553.
125. Arkenau HT, Plummer R, Molife LR, Olmos D, Yap TA, Squires M, Lewis S, Lock V, Yule M, Lyons J, Calvert H, Judson I. A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies. Ann Oncol 23(5):1307-13, 2012. e-Pub 2011. PMID: 22015452.
126. Yap TA, Cortes-Funes H, Shaw H, Rodriguez R, Olmos D, Lal R, Fong PC, Tan DS, Harris D, Capdevila J, Coronado C, Alfaro V, Soto-Matos A, Fernández-Teruel C, Siguero M, Tabernero JM, Paz-Ares L, de Bono JS, López-Martin JA. First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours. Br J Cancer 106(8):1379-85, 2012. PMID: 22491421.
127. Yap TA, Gerlinger M, Futreal PA, Pusztai L, Swanton C. Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med 4(127):127ps10, 2012. PMID: 22461637.
128. Yap TA, Swanton C, de Bono JS. Personalization of prostate cancer prevention and therapy: are clinically qualified biomarkers in the horizon?. EPMA J 3(1):3, 2012. e-Pub 2012. PMID: 22738151.
129. Perkins G, Yap TA, Pope L, Cassidy AM, Dukes JP, Riisnaes R, Massard C, Cassier PA, Miranda S, Clark J, Denholm KA, Thway K, Gonzalez De Castro D, Attard G, Molife LR, Kaye SB, Banerji U, de Bono JS. Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers. PLoS One 7(11):e47020, 2012. e-Pub 2012. PMID: 23144797.
130. Yap TA, Yan L, Patnaik A, Fearen I, Olmos D, Papadopoulos K, Baird RD, Delgado L, Taylor A, Lupinacci L, Riisnaes R, Pope LL, Heaton SP, Thomas G, Garrett MD, Sullivan DM, de Bono JS, Tolcher AW. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol 29(35):4688-95, 2011. e-Pub 2011. PMID: 22025163.
131. de Bono JS, Yap TA. Future directions in the evaluation of c-MET-driven malignancies. Ther Adv Med Oncol 3(1 Suppl):S51-60, 2011. PMID: 22128288.
132. de Bono JS, Yap TA. c-MET: an exciting new target for anticancer therapy. Ther Adv Med Oncol 3(1 Suppl):S3-5, 2011. PMID: 22128286.
133. Olmos D, Baird RD, Yap TA, Massard C, Pope L, Sandhu SK, Attard G, Dukes J, Papadatos-Pastos D, Grainger P, Kaye SB, de Bono JS. Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in phase I oncology trials. Clin Cancer Res 17(15):5188-96, 2011. e-Pub 2011. PMID: 21531820.
134. Brunetto A, Olmos D, Arkenau HT, Tan D, Yap TA, de Bono J, Barriuso J, Kaye S. Perceptions and referral trends into phase I oncology trials: results of a clinical survey. Journal of Oncology 2011, 2011. PMID: None.
135. Olmos D, Barker D, Sharma R, Brunetto AT, Yap TA, Taegtmeyer AB, Barriuso J, Medani H, Degenhardt YY, Allred AJ, Smith DA, Murray SC, Lampkin TA, Dar MM, Wilson R, de Bono JS, Blagden SP. Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies. Clin Cancer Res 17(10):3420-30, 2011. e-Pub 2011. PMID: 21459796.
136. Yap TA, Olmos D, Brunetto AT, Tunariu N, Barriuso J, Riisnaes R, Pope L, Clark J, Futreal A, Germuska M, Collins D, deSouza NM, Leach MO, Savage RE, Waghorne C, Chai F, Garmey E, Schwartz B, Kaye SB, de Bono JS. Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J Clin Oncol 29(10):1271-9, 2011. e-Pub 2011. PMID: 21383285.
137. Yap TA, Walton MI, Hunter LJ, Valenti M, de Haven Brandon A, Eve PD, Ruddle R, Heaton SP, Henley A, Pickard L, Vijayaraghavan G, Caldwell JJ, Thompson NT, Aherne W, Raynaud FI, Eccles SA, Workman P, Collins I, Garrett MD. Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930. Mol Cancer Ther 10(2):360-71, 2011. e-Pub 2010. PMID: 21191045.
138. Yap TA, de Bono JS, Kaye SB, Tutt A, Ashworth A, Schellens JHM. BRCA1 CpG Island Hypermethylation Predicts Sensitivity to PARP Inhibitors. Journal of Clinical Oncology 28(29):e565-6, 2010. PMID: None.
139. Brunetto AT, Ang JE, Olmos D, Tan D, Barriuso J, Arkenau HT, Yap TA, Molife LR, Banerji U, de Bono J, Judson I, Kaye S. A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit: unplanned admissions as an early indicator of patient attrition. Eur J Cancer 46(15):2739-45, 2010. e-Pub 2010. PMID: 20667711.
140. Yap TA, Vidal L, Adam J, Stephens P, Spicer J, Shaw H, Ang J, Temple G, Bell S, Shahidi M, Uttenreuther-Fischer M, Stopfer P, Futreal A, Calvert H, de Bono JS, Plummer R. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol 28(25):3965-72, 2010. e-Pub 2010. PMID: 20679611.
141. Molife LR, Fong PC, Paccagnella L, Reid AH, Shaw HM, Vidal L, Arkenau HT, Karavasilis V, Yap TA, Olmos D, Spicer J, Postel-Vinay S, Yin D, Lipton A, Demers L, Leitzel K, Gualberto A, de Bono JS. The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study. Br J Cancer 103(3):332-9, 2010. e-Pub 2010. PMID: 20628389.
142. Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, De Greve J, Lubinski J, Shanley S, Messiou C, A'Hern R, Tutt A, Ashworth A, Stone J, Carmichael J, Schellens JH, de Bono JS, Kaye SB. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 28(15):2512-9, 2010. e-Pub 2010. PMID: 20406929.
143. Gourley C, Michie CO, Roxburgh P, Yap TA, Harden S, Paul J, Ragupathy K, Todd R, Petty R, Reed N, Hayward RL, Mitchell P, Rye T, Schellens JH, Lubinski J, Carmichael J, Kaye SB, Mackean M, Ferguson M. Increased incidence of visceral metastases in scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype. J Clin Oncol 28(15):2505-11, 2010. e-Pub 2010. PMID: 20406939.
144. Grimshaw KM, Hunter LJ, Yap TA, Heaton SP, Walton MI, Woodhead SJ, Fazal L, Reule M, Davies TG, Seavers LC, Lock V, Lyons JF, Thompson NT, Workman P, Garrett MD. AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase that induces pharmacodynamic changes and inhibits human tumor xenograft growth. Mol Cancer Ther 9(5):1100-10, 2010. e-Pub 2010. PMID: 20423992.
145. Yap TA, Kaye SB, de Bono JS. Inhibition of poly(ADP-ribose) polymerase in BRCA mutation carriers. The New England Journal of Medicine 361(17):1707-1708, 2009. PMID: None.
146. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361(2):123-34, 2009. e-Pub 2009. PMID: 19553641.
147. Rasheed S, Yap TA, Zia A, McDonald PJ, Glynne-Jones R. Chemoradiotherapy – an alternative to surgery for squamous cell carcinoma of the rectum. Report of six cases and literature review. Colorectal Disease 11(2):191-7, 2009. PMID: None.
148. Vidal L, Pandha HS, Yap TA, White CL, Twigger K, Vile RG, Melcher A, Coffey M, Harrington KJ, DeBono JS. A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res 14(21):7127-37, 2008. PMID: 18981012.
149. Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper CS, Kaye SB, Dearnaley D, Lee G, de Bono JS. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 26(28):4563-71, 2008. e-Pub 2008. PMID: 18645193.
150. Haluska P, Shaw HM, Batzel GN, Yin D, Molina JR, Molife LR, Yap TA, Roberts ML, Sharma A, Gualberto A, Adjei AA, de Bono JS. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res 13(19):5834-40, 2007. PMID: 17908976.
151. Yap TA, Molife LR, Blagden SP, de Bono S. Targeting cell cycle kinases and kinesins in anticancer drug development. Expert Opin Drug Discov 2(4):539-60, 2007. PMID: 23484760.
152. Vidal L, Yap TA, White CL, Twigger K, Hingorani M, Kaye SB, Harrington KJ, de Bono JS. Reovirus and Oncolytic Viruses for the Targeted Treatment of Cancer. Targeted Oncology 1(3):130-150, 2006. PMID: None.
153. Hawkey CR, Yap TA, Pereira J, Moore DA, Davidson RN, Pasvol G, Kon OM, Wall RA, Wilkinson RJ. Characterization and management of paradoxical upgrading reactions in HIV-uninfected patients with lymph node tuberculosis. Clinical Infectious Diseases 40(9):1368-71, 2005. PMID: None.

Invited Articles

1. Yap TA, Zivi A, de Bono JS. Cabazitaxel: A novel drug strategy in castration resistant prostate cancer. Medicine Matters:1-7, 2011. PMID: None.
2. Yap TA. New York nightmare: disaster docs, the story of the emergency services. Trauma 1(1):6-7, 2001. PMID: None.

Manuals, Teaching Aids, Other Teaching Publications

1. Yap TA, Josephs D. The use of biomarkers for treatment decisions in oncology. ESMO E-Learning Module, http://oncologypro.esmo.org/Science-Education/ESMO-E-Learning-and-V-Learning/The-Use-of-Biomarkers-for-Treatment-Decisions-in-Oncology, 2015.
2. Yap TA, Biondo A. Tumour biology – new treatments and predictive biomarkers. The Institute of Cancer Research E-learning module, 2014.
3. Yap TA, Zivi A, de Bono JS. Cabazitaxel: A novel drug strategy in castration resistant prostate cancer. Medicine Matters, 2011.
4. Yap TA. New York nightmare: disaster docs, the story of the emergency services. Trauma, 2001.

Other Articles

1. Bzura A, Spicer JB, Dulloo S, Yap TA, Fennell DA Targeting DNA Damage Response Deficiency in Thoracic Cancers. Drugs None(None):None, 2024. PMID: 39001941.
2. Ngoi NYL, Pilie PG, McGrail DJ, Zimmermann M, Schlacher K, Yap TA Targeting ATR in patients with cancer. Nat Rev Clin Oncol 21(4):278-293, 2024. PMID: 38378898.
3. Bhamidipati D, Haro-Silerio JI, Yap TA, Ngoi N PARP inhibitors: enhancing efficacy through rational combinations. Br J Cancer 129(6):904-916, 2023. PMID: 37430137.
4. Alhalabi O, Groisberg R, Zinner R, Hahn AW, Naing A, Zhang S, Tsimberidou AM, Rodon J, Fu S, Yap TA, Hong DS, Sun M, Jiang Y, Pant S, Shah AY, Zurita A, Tannir NM, Vikram R, Roszik J, Meric-Bernstam F, Subbiah V Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies. NPJ Precis Oncol 7(1):37, 2023. PMID: 37072571.
5. Coleman N, Yap TA, Heymach JV, Meric-Bernstam F, Le X Antibody-drug conjugates in lung cancer: dawn of a new era?. NPJ Precis Oncol 7(1):5, 2023. PMID: 36631624.
6. Araujo D, Greystoke A, Bates S, Bayle A, Calvo E, Castelo-Branco L, de Bono J, Drilon A, Garralda E, Ivy P, Kholmanskikh O, Melero I, Pentheroudakis G, Petrie J, Plummer R, Ponce S, Postel-Vinay S, Siu L, Spreafico A, Stathis A, Steeghs N, Yap C, Yap TA, Ratain M, Seymour L Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022. Ann Oncol 34(1):48-60, 2023. PMID: 36182023.
7. Bright SJ, Flint DB, Martinus DKJ, Turner BX, Manandhar M, Kacem MB, McFadden CH, Yap TA, Shaitelman SF, Sawakuchi GO Targeted Inhibition of DNA-PKcs, ATM, ATR, PARP, and Rad51 Modulate Response to X Rays and Protons. None, 2022. PMID: None.
8. Vo HH, Fu S, Hong DS, Karp DD, Piha-Paul S, Subbiah V, Janku F, Naing A, Yap TA, Rodon J, Ajani JA, Cartwright C, Johnson A, Song IW, Beck J, Kahle M, Nogueras-Gonzalez GM, Miller V, Chao C, Vining DJ, Berry DA, Meric-Bernstam F, Tsimberidou AM Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology. NPJ Precis Oncol, 2022. PMID: None.
9. Moyers JT, Carmagnani Pestana R, Roszik J, Hong DS, Naing A, Fu S, Piha-Paul S, Yap T, Karp D, Rodon J, Livingston JA, Zarzour MA, Ravi V, Patel S, Benjamin RS, Ludwig J, Herzog C, Ratan R, Somaiah N, Conley A, Gorlick R, Meric-Bernstam F, Subbiah V Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102). None, 2022. PMID: None.
10. Ngoi NYL, Westin SN, Yap TA Targeting the DNA damage response beyond poly(ADP-ribose) polymerase inhibitors: novel agents and rational combinations. Curr Opin Oncol 34(5):559-569, 2022. PMID: 35787597.
11. Araujo D, Greystoke A, Bates S, Bayle A, Calvo E, Castelo-Branco L, de Bono J, Drilon A, Garralda E, Ivy P, Kholmanskikh O, Melero I, Pentheroudakis G, Petrie J, Plummer R, Ponce S, Postel-Vinay S, Siu L, Spreafico A, Stathis A, Steeghs N, Yap C, Yap TA, Ratain M, Seymour L Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022. Ann Oncol, 2022. PMID: None.
12. Mendoza TR, Hong DS, Peterson CB, Stephen B, Dumbrava E, Pant S, Tsimberidou AM, Yap TA, Sheshadri A, Altan M, George G, Castillo L, Rodriguez E, Gong J, Subbiah V, Janku F, Fu S, Piha-Paul SA, Ahnert JR, Karp DD, Cleeland C, Meric-Bernstam F, Naing A Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial. None, 2022. PMID: None.
13. Nelson BE, Ejezie CL, Stephen BA, Nardo M, Campbell E, Gong J, Hong DS, Fu S, Yap TA, Murphy MB, Piha-Paul S, Daver NG, Rojas-Hernandez CM, Naing A Spectrum of Immune Checkpoint Inhibitor Anemias: Results From a Single Center, Early-Phase Clinical Trials Case Series Experience. None, 2022. PMID: None.
14. Nelson BE, Ejezie CL, Stephen BA, Nardo M, Campbell E, Gong J, Hong DS, Fu S, Yap TA, Murphy MB, Piha-Paul S, Daver NG, Rojas-Hernandez CM, Naing A Spectrum of Immune Checkpoint Inhibitor Anemias: Results From a Single Center, Early-Phase Clinical Trials Case Series Experience. J Hematol 11(3):113-120, 2022. PMID: 35837373.
15. Yao S, Meric-Bernstam F, Hong D, Janku F, Naing A, Piha-Paul SA, Tsimberidou AM, Karp D, Subbiah V, Yap TA, Ahnert JR, Pant S, Dumbrava EEI, Wathoo C, Campbell E, Yu L, Yamamura Y, Fu S Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences. Sci Rep 12(1):8701, 2022. PMID: 35610322.
16. Thein KZ, Karp DD, Tsimberidou A, Gong J, Sulovic S, Shah J, Milton DR, Hong DS, Janku F, McQuinn L, Stephen BA, Colen R, Carter BW, Yap TA, Piha-Paul SA, Fu S, Meric-Bernstam F, Naing A Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single‑center, multi‑arm phase Ib study. Invest New Drugs 40(2):463, 2022. PMID: 34731355.
17. Ngoi NYL, Peng G, Yap TA A Tale of Two Checkpoints: ATR Inhibition and PD-(L)1 Blockade. Annu Rev Med 73(None):231-250, 2022. PMID: 34644155.
18. Ngoi NYL, Leo E, O'Connor MJ, Yap TA Development of Next-Generation Poly(ADP-Ribose) Polymerase 1-Selective Inhibitors. Cancer J 27(6):521-528, 2021. PMID: 34904816.
19. Ngoi NYL, Pham MM, Tan DSP, Yap TA Targeting the replication stress response through synthetic lethal strategies in cancer medicine. Trends Cancer 7(10):930-957, 2021. PMID: 34215565.
20. Hobbs EA, Litton JK, Yap TA Development of the PARP inhibitor talazoparib for the treatment of advanced BRCA1 and BRCA2 mutated breast cancer. Expert Opin Pharmacother 22(14):1825-1837, 2021. PMID: 34309473.
21. Jhaveri K, Burris Rd HA, Yap TA, Hamilton E, Rugo HS, Goldman JW, Dann S, Liu F, Wong GY, Krupka H, Shapiro GI The evolution of cyclin dependent kinase inhibitors in the treatment of cancer. Expert Rev Anticancer Ther 21(10):1105-1124, 2021. PMID: 34176404.
22. Pham MM, Ngoi NYL, Peng G, Tan DSP, Yap TA Development of poly(ADP-ribose) polymerase inhibitor and immunotherapy combinations: progress, pitfalls, and promises. Trends Cancer 7(10):958-970, 2021. PMID: 34158277.
23. Yap TA, Parkes EE, Peng W, Moyers JT, Curran MA, Tawbi HA Development of Immunotherapy Combination Strategies in Cancer. Cancer Discov 11(6):1368-1397, 2021. PMID: 33811048.
24. Collins DC, Sundar R, Constantinidou A, Dolling D, Yap TA, Popat S, O'Brien ME, Banerji U, de Bono JS, Lopez JS, Tunariu N, Minchom A Correction to: Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease. BMC Cancer 21(1):245, 2021. PMID: 33685408.
25. Majd NK, Yap TA, Koul D, Balasubramaniyan V, Li X, Khan S, Gandy KS, Yung WKA, de Groot JF The promise of DNA damage response inhibitors for the treatment of glioblastoma. Neurooncol Adv 3(1):vdab015, 2021. PMID: 33738447.
26. Coleman N, Moyers JT, Harbery A, Vivanco I, Yap TA Clinical Development of AKT Inhibitors and Associated Predictive Biomarkers to Guide Patient Treatment in Cancer Medicine. Pharmgenomics Pers Med 14:1517-1535, 2021. PMID: 34858045.
27. Yap TA, Jacobs I, Baumfeld Andre E, Lee LJ, Beaupre D, Azoulay L Application of Real-World Data to External Control Groups in Oncology Clinical Trial Drug Development. Front Oncol 11(None):695936, 2021. PMID: 35070951.
28. Pilie PG, Gay CM, Byers LA, O'Connor MJ, Yap TA PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers. Clin Cancer Res 25(13):3759-3771, 2019. PMID: 30760478.
29. George GC, Barata PC, Campbell A, Chen A, Cortes JE, Hyman DM, Jones L, Karagiannis T, Klaar S, Le-Rademacher JG, LoRusso P, Mandrekar SJ, Merino DM, Minasian LM, Mitchell SA, Montez S, O'Connor DJ, Pettit S, Silk E, Sloan JA, Stewart M, Takimoto CH, Wong GY, Yap TA, Cleeland CS, Hong DS Improving attribution of adverse events in oncology clinical trials. Cancer Treat Rev 76(None):33-40, 2019. PMID: 31108240.
30. Pilie PG, Tang C, Mills GB, Yap TA State-of-the-art strategies for targeting the DNA damage response in cancer. Nat Rev Clin Oncol 16(2):81-104, 2019. PMID: 30356138.
31. Yap TA, Plummer R, Azad NS, Helleday T The DNA Damaging Revolution: PARP Inhibitors and Beyond. Am Soc Clin Oncol Educ Book 39(None):185-195, 2019. PMID: 31099635.
32. Stewart RA, Pilie PG, Yap TA Development of PARP and Immune-Checkpoint Inhibitor Combinations. Cancer Res 78(24):6717-6725, 2018. PMID: 30498083.
33. Kurnit KC, Dumbrava EEI, Litzenburger B, Khotskaya YB, Johnson AM, Yap TA, Rodon J, Zeng J, Shufean MA, Bailey AM, Sanchez NS, Holla V, Mendelsohn J, Shaw KM, Bernstam EV, Mills GB, Meric-Bernstam F Precision Oncology Decision Support: Current Approaches and Strategies for the Future. Clin Cancer Res 24(12):2719-2731, 2018. PMID: 29420224.
34. Janku F, Yap TA, Meric-Bernstam F Targeting the PI3K pathway in cancer: are we making headway?. Nat Rev Clin Oncol 15(5):273-291, 2018. PMID: 29508857.
35. Raghav K, Bailey AM, Loree JM, Kopetz S, Holla V, Yap TA, Wang F, Chen K, Salgia R, Hong D Untying the gordion knot of targeting MET in cancer. Cancer Treat Rev 66(None):95-103, 2018. PMID: 29730462.
36. Yap TA, Aerts JG, Popat S, Fennell DA Novel insights into mesothelioma biology and implications for therapy. Nat Rev Cancer 17(8):475-488, 2017. PMID: 28740119.
37. Sundar R, Brown J, Ingles Russo A, Yap TA Targeting ATR in cancer medicine. Curr Probl Cancer 41(4):302-315, 2017. PMID: 28662958.
38. Dolly SO, Collins DC, Sundar R, Popat S, Yap TA Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer. Drugs 77(8):813-827, 2017. PMID: 28378229.
39. Kumar R, Collins D, Dolly S, McDonald F, O'Brien MER, Yap TA Targeting the PD-1/PD-L1 axis in non-small cell lung cancer. Curr Probl Cancer 41(2):111-124, 2017. PMID: 28214087.
40. Brown JS, O'Carrigan B, Jackson SP, Yap TA Targeting DNA Repair in Cancer: Beyond PARP Inhibitors. Cancer Discov 7(1):20-37, 2017. PMID: 28003236.
41. Collins DC, Sundar R, Lim JSJ, Yap TA Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics. Trends Pharmacol Sci 38(1):25-40, 2017. PMID: 27871777.
42. Yap TA, Macklin-Doherty A, Popat S Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancer. Eur J Cancer 70(None):12-21, 2017. PMID: 27866095.
43. Lim JS, Sundar R, Chenard-Poirier M, Lopez J, Yap TA Emerging biomarkers for PD-1 pathway cancer therapy. Biomark Med 11(1):53-67, 2017. PMID: 27936870.
44. Sundar R, Chenard-Poirier M, Collins DC, Yap TA Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer. Front Med (Lausanne) 4(None):39, 2017. PMID: 28443282.
45. Yap TA, Smith AD, Ferraldeschi R, Al-Lazikani B, Workman P, de Bono JS Drug discovery in advanced prostate cancer: translating biology into therapy. Nat Rev Drug Discov 15(10):699-718, 2016. PMID: 27444228.
46. Sharp A, Bhosle J, Abdelraouf F, Popat S, O'Brien M, Yap TA Development of molecularly targeted agents and immunotherapies in small cell lung cancer. Eur J Cancer 60(None):26-39, 2016. PMID: 27060747.
47. Weller A, O'Brien MER, Ahmed M, Popat S, Bhosle J, McDonald F, Yap TA, Du Y, Vlahos I, deSouza NM Mechanism and non-mechanism based imaging biomarkers for assessing biological response to treatment in non-small cell lung cancer. Eur J Cancer 59(None):65-78, 2016. PMID: 27016624.
48. Yap TA, Bjerke L, Clarke PA, Workman P Drugging PI3K in cancer: refining targets and therapeutic strategies. Curr Opin Pharmacol 23:98-107, 2015. PMID: 26117819.
49. Lopez J, Harris S, Roda D, Yap TA Precision Medicine for Molecularly Targeted Agents and Immunotherapies in Early-Phase Clinical Trials. Transl Oncogenomics 7(Suppl 1):1-11, 2015. PMID: 26609214.
50. Smith AD, Roda D, Yap TA Strategies for modern biomarker and drug development in oncology. J Hematol Oncol 7:70, 2014. PMID: 25277503.
51. Yap TA, Lorente D, Omlin A, Olmos D, de Bono JS Circulating tumor cells: a multifunctional biomarker. Clin Cancer Res 20(10):2553-68, 2014. PMID: 24831278.
52. Yap TA, Popat S Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer. Pharmgenomics Pers Med 7:285-95, 2014. PMID: 25278773.
53. Yap TA, Popat S The role of afatinib in the management of non-small cell lung carcinoma. Expert Opin Drug Metab Toxicol 9(11):1529-39, 2013. PMID: 23985030.
54. Khan KH, Yap TA, Yan L, Cunningham D Targeting the PI3K-AKT-mTOR signaling network in cancer. Chin J Cancer 32(5):253-65, 2013. PMID: 23642907.
55. Yap TA, Omlin A, de Bono JS Development of therapeutic combinations targeting major cancer signaling pathways. J Clin Oncol 31(12):1592-605, 2013. PMID: 23509311.
56. Yap TA, Pezaro CJ, de Bono JS Cabazitaxel in metastatic castration-resistant prostate cancer. Expert Rev Anticancer Ther 12(9):1129-36, 2012. PMID: 23098113.
57. Basu B, Yap TA, Molife LR, de Bono JS Targeting the DNA damage response in oncology: past, present and future perspectives. Curr Opin Oncol 24(3):316-24, 2012. PMID: 22476188.
58. Vitfell-Pedersen J, Yap TA, Moreno V, Baird RD, Khan AZ, Barton DP, Kaye SB The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials. Eur J Gynaecol Oncol 33(2):211-3, 2012. PMID: 22611966.
59. Yap TA, Workman P Exploiting the cancer genome: strategies for the discovery and clinical development of targeted molecular therapeutics. Annu Rev Pharmacol Toxicol 52:549-73, 2012. PMID: 22235862.
60. Yap TA, Sandhu SK, Alam SM, de Bono JS HGF/c-MET targeted therapeutics: novel strategies for cancer medicine. Curr Drug Targets 12(14):2045-58, 2011. PMID: 21777195.
61. Sandhu SK, Yap TA, de Bono JS The emerging role of poly(ADP-Ribose) polymerase inhibitors in cancer treatment. Curr Drug Targets 12(14):2034-44, 2011. PMID: 21777194.
62. Yap TA, Olmos D, Molife LR, de Bono JS Targeting the insulin-like growth factor signaling pathway: figitumumab and other novel anticancer strategies. Expert Opin Investig Drugs 20(9):1293-304, 2011. PMID: 21777167.
63. Yap TA, Zivi A, Omlin A, de Bono JS The changing therapeutic landscape of castration-resistant prostate cancer. Nat Rev Clin Oncol 8(10):597-610, 2011. PMID: 21826082.
64. Yap TA, Sandhu SK, Carden CP, de Bono JS Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic. CA Cancer J Clin 61(1):31-49, 2011. PMID: 21205831.
65. Carden CP, Yap TA, Kaye SB PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancers. Curr Opin Oncol 22(5):473-80, 2010. PMID: 20485165.
66. Yap TA, Sandhu SK, Workman P, de Bono JS Envisioning the future of early anticancer drug development. Nat Rev Cancer 10(7):514-23, 2010. PMID: 20535131.
67. Yap TA, de Bono JS Targeting the HGF/c-Met axis: state of play. Mol Cancer Ther 9(5):1077-9, 2010. PMID: 20442310.
68. Carden CP, Sarker D, Postel-Vinay S, Yap TA, Attard G, Banerji U, Garrett MD, Thomas GV, Workman P, Kaye SB, de Bono JS Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?. Drug Discov Today 15(3-4):88-97, 2010. PMID: 19961955.
69. Sandhu SK, Yap TA, de Bono JS Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective. Eur J Cancer 46(1):9-20, 2010. PMID: 19926276.
70. Sarker D, Reid AH, Yap TA, de Bono JS Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res 15(15):4799-805, 2009. PMID: 19638457.
71. Yap TA, Carden CP, Kaye SB Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer 9(3):167-81, 2009. PMID: 19238149.
72. Yap TA, Brunetto A, Pandha H, Harrington K, Debono JS Reovirus therapy in cancer: has the orphan virus found a home?. Expert Opin Investig Drugs 17(12):1925-35, 2008. PMID: 19012507.
73. Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS, Workman P Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol 8(4):393-412, 2008. PMID: 18721898.
74. Yap TA, Carden CP, Attard G, de Bono JS Targeting CYP17: established and novel approaches in prostate cancer. Curr Opin Pharmacol 8(4):449-57, 2008. PMID: 18619560.
75. Yap TA, Eisen TG Adjuvant therapy of renal cell carcinoma. Clin Genitourin Cancer 5(2):120-30, 2006. PMID: 17026800.

Editorials

1. Torrado C, Plummer R, Yap TA. Poly(ADP-Ribose) Polymerase Inhibitor Development: Promising Strategies to Move Beyond Approved Indications. JCO Precis Oncol 8(None):e2400204, 2024. PMID: 38865670.
2. Yap, TA, Shapiro, GI. Preface. Cancer treatment and research 186:v-vi, 2024. PMID: None.
3. Drilon A, Sharma MR, Johnson ML, Yap TA, Gadgeel S, Nepert D, Feng G, Reddy MB, Harney AS, Elsayed M, Cook AW, Wong CE, Hinklin RJ, Jiang Y, Brown EN, Neitzel NA, Laird ER, Wu WI, Singh A, Wei P, Ching KA, Gaudino JJ, Lee PA, Hartley DP, Rothenberg SM. SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy. Cancer Discov 13(8):1789-1801, 2023. PMID: 37269335.
4. Yap TA, Johnson A, Meric-Bernstam F. Precision Medicine in Oncology-Toward the Integrated Targeting of Somatic and Germline Genomic Aberrations. JAMA Oncol 7(4):507-509, 2021. PMID: 33630035.
5. Coleman N, Zhang B, Byers LA, Yap TA. The role of Schlafen 11 (SLFN11) as a predictive biomarker for targeting the DNA damage response. Br J Cancer 124(5):857-859, 2021. PMID: 33328609.
6. Yam C, Ma BBY, Yap TA. Global Implementation of Precision Oncology. JCO Precis Oncol 5(None):None, 2021. PMID: 34250385.
7. Pilie PG, George A, Yap TA. Patient selection biomarker strategies for PARP inhibitor therapy. Ann Oncol 31(12):1603-1605, 2020. PMID: 33011228.
8. Ileana Dumbrava EE, Mills GB, Yap TA. Targeting gamma secretase: has progress moved up a Notch?. Ann Oncol 29(9):1889-1891, 2018. PMID: 30084907.
9. Ileana Dumbrava E, Meric-Bernstam F, Yap TA. Challenges with biomarkers in cancer drug discovery and development. Expert Opin Drug Discov 13(8):685-690, 2018. PMID: 29792354.
10. Subbiah V, Rodon J, Yap TA. Precision oncology: East meets West. Int J Cancer 142(9):1734-1737, 2018. PMID: 29243227.
11. Lam M, Pant S, Yap TA. Combination drug development in BRAF mutant colorectal cancer. Oncoscience 5(3-4):51-53, 2018. PMID: 29854866.
12. Takebe N, Yap TA. Precision medicine in oncology. Curr Probl Cancer 41(3):163-165, 2017. PMID: 28372822.
13. Yap TA, Popat S. Targeting MET Exon 14 Skipping Alterations: Has Lung Cancer MET Its Match?. J Thorac Oncol 12(1):12-14, 2017. PMID: 27988098.
14. Lim JS, Collins D, Yap TA. Emerging strategies for the treatment of advanced small cell lung cancer. J Thorac Dis 8(10):E1249-E1253, 2016. PMID: 27867600.
15. Brown JS, Kaye SB, Yap TA. PARP inhibitors: the race is on. Br J Cancer 114(7):713-5, 2016. PMID: 27022824.

Abstracts

1. Ngoi NYL, Westin SN, Yap TA. Targeting the DNA damage response beyond poly(ADP-ribose) polymerase inhibitors: novel agents and rational combinations. Curr Opin Oncol, 2022. PMID: None.
2. Li X, Dowling EK, Yan G, Dereli Z, Bozorgui B, Imanirad P, Elnaggar JH, Luna A, Menter DG, Pilié PG, Yap TA, Kopetz S, Sander C, Korkut A. Precision Combination Therapies Based on Recurrent Oncogenic Coalterations. None, 2022. PMID: None.
3. Yap TA, Gainor JF, Callahan MK, Falchook GS, Pachynski RK, LoRusso P, Kummar S, Gibney GT, Burris HA, Tykodi SS, Rahma OE, Seiwert TY, Papadopoulos KP, Blum Murphy M, Park H, Hanson A, Hashambhoy-Ramsay Y, McGrath L, Hooper E, Xiao X, Cohen H, Fan M, Felitsky D, Hart C, McComb R, Brown K, Sepahi A, Jimenez J, Zhang W, Baeck J, Laken H, Murray R, Trehu E, Harvey CJ. First in Human Phase 1/2 ICONIC Trial of the ICOS agonist vopratelimab alone and with nivolumab: ICOS high CD4 T cell populations and predictors of response. None, 2022. PMID: None.
4. Yap TA, Ashok A, Stoll J, Mauer E, Nepomuceno VM, Blackwell KL, Garber JE, Meric-Bernstam F. Prevalence of Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testing Guidelines. JAMA, 2022. PMID: None.
5. Yao S, Meric-Bernstam F, Hong D, Janku F, Naing A, Piha-Paul SA, Tsimberidou AM, Karp D, Subbiah V, Yap TA, Ahnert JR, Pant S, Dumbrava EEI, Wathoo C, Campbell E, Yu L, Yamamura Y, Fu S. Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences. Sci. Rep, 2022. PMID: None.
6. Yap TA, Bessudo A, Hamilton E, Sachdev J, Patel MR, Rodon J, Evilevitch L, Duncan M, Guo W, Kumar S, Lu S, Dezube BJ, Gabrail N. IOLite: phase Ib trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin-paclitaxel, with or without bevacizumab in patients with advanced cancer. J Immunother Cancer, 2022. PMID: None.
7. Surana R, Rogers JE, Nogueras-Gonzalez GM, Hong DS, Yap TA, Rodon Ahnert J, Naing A, Wolff RA, Smalgo BG, Meric-Bernstam F, Subbiah V, Pant S. Prognostic factors associated with survival in patients with pancreatic cancer treated on early phase immune-checkpoint inhibitor clinical trials. ASCO Gastrointestinal Cancers Symposium, 2022. PMID: None.
8. Yap TA, Basu C, Goldman JW, Gordon M, Hamilton E, Kelly A, Liu F, Moreau AR, Neumann H, Papadopoulos K, Rugo HS, Shapiro GI, Vinayak S, Zhou L, Jhaveri K. A first-in-human phase 1/2a dose escalation/expansion study of the first-in-class CDK2/4/6 inhibitor PF‑06873600 alone or with endocrine therapy in patients with breast or ovarian cancer. San Antonio Breast Cancer Symposium (SABCS), 2021. PMID: None.
9. Kuplast-Barr K, Johnson M, Patel M, Yap T, Falchook G, LoRusso P, Abo R, Liu C, Manyak E, Cleary L, Bozon V, Parasuraman S, Keilhack H, McEachern K. RBN-2397, A Novel, Potent, And Selective Parp7 Inhibitor, Induces Tumor-Intrinsic Type I Interferon Responses and Adaptive Immunity In Preclinical Models And Patient Tumors. SITC Annual Meeting 2021, 2021. PMID: None.
10. Yap T, Barve M, Gainor J, Bockorny B, Ju Y, Cote S, Bilic S, Liu L, Chyung Y, Legler M, Gan L, McKean M. First-In-Human Phase 1 Trial Of SRK-181: A Latent TGFB1 Inhibitor, Alone Or In Combination With Anti-PD-(L)1 Treatment In Patients With Advanced Solid Tumors (Dragon Trial). SITC Annual Meeting 2021, 2021. PMID: None.
11. Ngoi NYL, Peng G, Yap TA. A Tale of Two Checkpoints: ATR Inhibition and PD-(L)1 Blockade. None, 2021. PMID: None.
12. Papadopoulos K, Yap TA, Piha-Paul SA, Lorusso P, Hu-Lieskovan S, Shepherd CJ, Marshall S, Holz J, Poon E, Grabowska UB, Kayitalire L. A first-in-human phase I study of FS120, an OX40/CD137 tetravalent bispecific antibody, in patients with advanced malignancies. ESMO Congress 2021, 2021. PMID: None.
13. Moyers J, Nguyen D, Hong DS, Ileana Dumbrava E, Fu S, Karp D, Naing A, Pant S, Janku F, Piha-Paul S, Rodon J, Subbiah V, Tsimberidou AM, Meric-Bernstam F, Yap TA. Adherence to the Food and Drug Administration (FDA) Guidance for the Co-Development of Two or More Investigational New Drugs in Phase 1/2 Cancer Trials. ESMO Congress 2021, 2021. PMID: None.
14. Burton E, Ileana Dumbrava EE, Peng W, Milton D, Amaria R, Mcquade J, Glitza IC, Hong D, Patel S, Rodon J, Yap TA, Naing A, Piha-Paul SA, Balmes G, Lazar A, Meric-Bernstam F, Hwu P, Davies MA, Tawbi HA. Ph I/II study of PI3K-β inhibitor GSK2636771 (G771) in combination with pembrolizumab (P) in patients (pts) with PTEN loss and melanoma or other advanced solid tumors. ESMO Congress 2021, 2021. PMID: None.
15. Saavedra Santa Gadea O, Greil R, de Jonge MJA, Tan D, Jerusalem G, Damien S, Grell P, Wainberg ZA, Wolf J, Joerger M, Carlino MS, Kasper S, Yap TA, Otero J, Yang X, Nesbitt V, Kim J, Ho Lee L, Choudhury S, Leal TA. Phase (Ph) II study of taminadenant (NIR178) + spartalizumab (PDR001) in patients (pts) with microsatellite stable (MSS) colorectal cancer (CRC). ESMO Congress 2021, 2021. PMID: None.
16. 1Do KT, Chow LQM, Reckamp K, Sanborn RE, Burris H, Robert F, Camidge RD, Steuer CE, Strickler JH, Weise A, Specht JM, Gutierrez M, Haughney P, Hengel S, Derleth CL, Yap TA. First-in-Human, First-in-Class, Phase I Trial of the Fucosylation Inhibitors SGN-2FF in Patients with Advanced Solid Tumors. None, 2021. PMID: None.
17. Yap TA, Barve M, Gainor J, Weekes C, Bockorny B, Ju Y, Faucette R, Bilic S, Lee-Hoeflich S, Song G, Chyung Y, Legler M, Gan L, Bendell J. First-in-human phase 1 trial (DRAGON) of SRK-181, a potential first-in-class selective latent TGFβ1 inhibitor, alone or in combination with anti-PD-(L)1 treatment in patients with advanced solid tumors. ASCO Annual Meeting 2021, 2021. PMID: None.
18. Zeineddine F, Garmezy B, Yap TA, Shen J. A more precise classifier of POLE mutations to identify candidates for immune therapy. ASCO Annual Meeting 2021, 2021. PMID: None.
19. Vo H, Fu S, Hong D, Karp D, Piha-Paul S, Subbiah V, Janku F, Naing A, Yap TA, Ahnert J, Ajani J, Cartwright C, Naqvi M, Nogueras-Gonzalez G, Miller V, Palmer G, Vining D, Berry D, Meric-Bernstam F, Tsimberidou A. Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT2): Challenges and Opportunities in Conducting an MD Anderson Randomized Study in Precision Oncology. ASCO Annual Meeting 2021, 2021. PMID: None.
20. Falchook G, Patel M, Yap TA, McEachern K, Kuplast-Barr K, Utley L, Cleary L, Manyak E, Bozon V, Parasuraman S, Johnson M. A first-in-human phase 1 study of a novel PARP7 inhibitor RBN-2397 in patients with advanced solid tumors. ASCO Annual Meeting 2021, 2021. PMID: None.
21. Yap TA, Tolcher A, Plummer E, Becker A, Fleuranceau-Morel P, Goddemeier T, Locatelli G, Gounaris I, De Bono J. A first-in-human phase I study of ATR inhibitor M1774 in patients with solid tumors. ASCO Annual Meeting 2021, 2021. PMID: None.
22. Yap TA, Dumbrava EE, Rodon Ahnert J, Hong DS, Pant S, Karp DD, Piha-Paul SA, Subbiah V, Tsimberidou AM, Fu S, Janku F, Montez S, Ahmad-Taha MT, Guerrero D, Nazarenko NN, Moore Y, Soth M, Kovacs J, Heffernan TP, Jones P. First-in-human biomarker-driven phase I trial of the potent and selective glutaminase-1 (GLS1) inhibitor IACS-6274 (IPN60090) in patients (pts) with molecularly selected advanced solid tumors. ASCO Annual Meeting 2021, 2021. PMID: None.
23. Abo-Zahrah R, Karp D, Adat A, Yap TA, Fu S, Ahnert J, Piha-Paul S, Tsimberidou A, Naing A, Subbiah V, Dumbrava E, Overman M, Patel S, Amaria R, Westin S, Meric-Bernstam F, Janku F. Patients with advanced solid cancers treated with ERK inhibitors exhibit pseudo-progession in lymphatic nodes. ASCO Annual Meeting 2021, 2021. PMID: None.
24. Lynch R, Bendell J, Advani R, Falchook G, Munster P, Patel M, Gutierrez M, Burness M, Palmisiano N, Hamadani M, Bradley W, O'Shea T, Doleman S, Renschler M, Englert J, Yap TA. First-in-human phase I/II study of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination in patients with advanced solid and hematologic cancers. ASCO Annual Meeting 2021, 2021. PMID: None.
25. Dumbrava E, Shapiro G, Bendell J, Yap TA, Jeselsohn R, Lepley D, Hurley S, Lin K, Liao M, Habeck J, Enke A, Hamilton E. Phase 1b/2 SEASTAR trial: Safety, pharmacokinetics, and preliminary efficacy of the poly(ADP)-ribose polymerase (PARP) inhibitor rucaparib and angiogenesis inhibitor lucitanib in patients with advanced solid tumors. ASCO Annual Meeting 2021, 2021. PMID: None.
26. Yap TA, Ashok A, Stoll J, Schwarzbach A, Blackwell K, Li T, Kang H, Garber J, Meric-Bernstam F. Rate of incidental germline findings detected by tumor-normal matched sequencing in cancer types lacking hereditary cancer testing guidelines. ASCO Annual Meeting 2021, 2021. PMID: None.
27. DiPeri TP, Evans KW, Tzeng CD, Kwong L, Kahle MP, Zheng X, Li D, Tran Cao HS, Vu T, Kim S, Su F, Kirby B, Wathoo C, Raso G, Rizvi Y, Wang H, Janku F, Shaw K, Yap T, Javle M, Rodon J, Meric-Bernstam F. The MD Anderson patient-derived xenograft series for modeling precision oncology in biliary tract cancers. AACR Annual Meeting 2021, 2021. PMID: None.
28. Johnson A, Ng PK, Kahle M, Castillo J, Amador B, Holla V, Vu T, Huang L, Su F, Kim S, Zeng J, Shufean MA, Conway T, Shaw KR, Yap TA, Rodon J, Meric-Bernstam F. Patient-specific, tiered, variant-level actionability correlates with functional effect in growth survival assay. AACR Annual Meeting 2021, 2021. PMID: None.
29. Spencer ND, Bristow CA, Guilani V, Miller MA, Carugo A, Harris AL, Minelli R, Feng N, Chang Q, Soth MJ, Le K, Weinstein JN, Lorenzi PL, Liu J, Wang W, Yap TA, Draetta G, Jones P, Heffernan TP, Kovacs JJ. Asparagine synthetase (ASNS) expression predicts response to the GLS1 inhibitor IPN60090 in ovarian cancer through selective modulation of redox homeostasis. AACR Annual Meeting 2021, 2021. PMID: None.
30. Suzuki E, Molina J, Spencer ND, Bristow CA, Harris AL, Feng N, Mahendra M, Gera S, Soth MJ, Le K, Yap TA, Draetta G, Jones P, Heffernan TP, Kovacs JJ. The GLS1 inhibitor IPN60090 enhances antitumor immune response through metabolic reprogramming of T cells and impacts on the tumor microenvironment. AACR Annual Meeting 2021, 2021. PMID: None.
31. Kovacs JJ, Spencer ND, Bristow CA, Carugo A, Giluiani V, Miller MA, Harris AL, Feng N, Soth ML, Le K, De Stanchina E, Rudin CM, Draetta G, Yap TA, Jones P, Heffernan TP. Integrated approach towards defining mechanism based combinations to guide clinical development of glutaminase inhibitors. AACR Annual Meeting 2021, 2021. PMID: None.
32. Alhalabi O, Naing A, Groisberg R, Hahn A, Zhang S, Berkey SC, Tsimberidou AM, Rodon J, Yap TA, Pant S, Shah AY, Zurita-Saavedra A, Tannir N, Meric-Bernstam F, Subbiah V. Phase I study of mTORC1-2 inhibitor sapanisertib (TAK-228) in combination with carboplatin plus paclitaxelin patients with advanced solid malignancies and mTOR pathway alterations. AACR Annual Meeting 2021, 2021. PMID: None.
33. Pant S, Shah A, Msaouel P, Campbell MT, Tu S, Gao J, Blumenschein GR, Mott F, Le X, Altan M, Meric-Bernstam F, Yap TA, Subbiah V, Rodon J, Glasmacher A, Mulder I, Chisamore MJ, Stevenson A, Tannir NM. Safety and efficacy signals in the complete phase I study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients refractory to immune checkpoint inhibitors (ICIs). SITC Annual Meeting 2020, 2020. PMID: None.
34. Yap TA, Dhawan M, Hendifar AE, Maio M, Owonikoko TK, Quintela-Fandino M, Shapira-Frommer R, Saraf S, Qiu P, Jin F, Gozman A, Levine DA. Olaparib plus pembrolizumab in patients with previously treated advanced solid tumors with homologous recombination repair mutation and/or homologous recombination repair deficiency: KEYLYNK-007. SITC Annual Meeting 2020, 2020. PMID: None.
35. Naing A, Karp DD, Piha-Paul SA, Haymaker C, Parra ER, Yang F, Pant S, Hong DS, Fu S, Yap TA, Stephen B, Yang Y, Lin H, Hong Leung C, Daver N, Choi Y, Hajjar J, Wistuba I, Hwu PM, Meric-Bernstam F, Rodon J. Immune correlates associated with clinical outcomes in patients with advanced malignancies treated with avelumab and OX40 agonist. SITC Annual Meeting 2020, 2020. PMID: None.
36. Pant S, Shah A, Msaouel P, Campbell MT, Tu S, Gao J, Blumenschein GR, Mott F, Le X, Altan M, Meric-Bernstam F, Yap TA, Subbiah V, Rodon J, Glasmacher A, Mulder I, Chisamore MJ, Stevenson A, Tannir NM. A phase I/II study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients refractory to immune checkpoint inhibitors. SITC Annual Meeting 2020, 2020. PMID: None.
37. Murthy R, Sheth RA, Tam A, Gupta S, Subbiah V, Janku F, Yap TA, Diab A, Naing A, Patel S, Meric-Bernstam F. Intra-Tumor Immunotherapy Injections utilizing Image guidance in Interventional Radiology: Clinical Trial Experience at a Tertiary care Cancer Center. SITC Annual Meeting 2020, 2020. PMID: None.
38. Sahebjam S, Muzaffer J, Yap TA, Hong DS, Rixe O, Brown-Glaberman U, Varga A, Massard C, Baldini C, Efuni S, Kapelan B, Liu Y, Ogunmefun E, Tayama T, Zhao H, Healy DJ, Latek R, Nakashima D, Yilmaz E. Safety and antitumor activity of indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor KHK2455 in combination with anti-CCR4 monoclonal antibody mogamulizumab in patients with advanced solid tumors. SITC Annual Meeting 2020, 2020. PMID: None.
39. Yap TA, Wong DJ, Hu-Lieskovan S, Papadopoulos KP, Morrow M, Grabowska U, Gliddon D, Holz J, LoRusso P. A first-in-human study of FS118, a tetravalent bispecific antibody targeting LAG-3 and PD-L1, in patients with advanced cancer and resistance to PD-(L)1 therapy. SITC Annual Meeting 2020, 2020. PMID: None.
40. Yap TA, Hamilton EP, Bauer TM, IIleana Dumbrava EE, Jeselsohn R, Enke A, Hurley S, Lin KK, Wride K, Giordano, Shapiro G. Rucaparib + sacituzumab govitecan (SG): Initial data from the phase Ib/II SEASTAR study (NCT03992131). ESMO Virtual Congress 2020, 2020. PMID: None.
41. Alhalabi A, Hahn AW, Msaouel P, Meric-Bernstam F, Naing A, Piha-Paul S, Janku F, Pant S, Yap TA, Hong DS, Fu S, Karp DD, Campbell E, Campbell MT, Shah AY, Tannir N, Siefker-Radtke AO, Gao J, Roszik J, Subbiah V. Validation of prognostic scores in patients with metastatic bladder carcinoma (mBC) enrolled in early phase clinical trials. ESMO Virtual Congress 2020, 2020. PMID: None.
42. Thein KZ, Tsimberidou AM, Piha-Paul S, Janku F, Karp DD, Fu S, Zarifa A, Gong J, Yap TA, Hong DS, Subbiah V, Pant S, Meric-Bernstam F, Naing A. Selinexor in combination with carboplatin and paclitaxel in patients with advanced or metastatic solid tumours: Results of an open label, single-center, multi-arm phase Ib study. ESMO Virtual Congress 2020, 2020. PMID: None.
43. Gheeya JS, Goswamy R, Garmezy B, Pilie PG, Wang W, Lee S, Javle M, Rodon J, Mills Shaw KR, Meric-Bernstam F, Yap TA. Clinical characteristics and therapeutic implications of PALB2 variants in patients with advanced solid tumors. ESMO Virtual Congress 2020, 2020. PMID: None.
44. Yap TA, Dhawan M, Hendifar AE, Maio M, Owonikoko TK, Quinteia-Fandino M, ShapiraFrommer R, Saraf S, Qiu P, Jin F, Gozman A, Levine DA. A phase 2 of olaparib in combination with pembrolizumab in patients with previously treated advanced solid tumors with homologous recombination repair mutation (HRRm) and/or homologous recombination repair deficiency (HRD): KEYLYNK-007. AACR Annual Meeting 2020, 2020. PMID: None.
45. Yap TA, Chen Y, Butler LH, Lao-Sirieix S, Cadogan E, O’Connor LO, Vishwanathan K, Kim Y, Landers D, Dean E. AZD7648: A Phase I/IIa first-in-human trial of a novel, potent and selective DNA-PK inhibitor in patients with advanced malignancies. AACR Annual Meeting 2020, 2020. PMID: None.
46. Pilie PG, Gheeya JS, Kyewalabye K, Goswamy RV, Wani KM, Le H, Campbell E, Sanchez NS, Yang D, Garmezy B, Ileana Dumbrava EE, Rodon Ahnert J, Heffernan T, Holla V, Shaw KR, Meric-Bernstam F, Lazar AJ, Wang W, Yap TA. Identifying functional loss of ATM gene in patients with advanced cancer. ASCO Annual Meeting 2020, 2020. PMID: None.
47. Yap TA, Dhawan MS, Hendifar AE, Maio M, Owonikoko TK, Quientia-Fandino M, Shapira R, Saraf A, Qiu P, Jin F, Gozman A, Levine DA. A phase II study of olaparib in combination with pembrolizumab in patients with previously treated advanced solid tumors with homologous recombination repair mutation (HRRm) and/or homologous recombination repair deficiency (HRD): KEYLYNK-007. ASCO Annual Meeting 2020, 2020. PMID: None.
48. Alhalabi O, Hahn AW, Meric-Bernstam F, Naing A, Piha-Paul SA, Janku F, Pant S, Yap TA, Hong DS, Fu S, Campbell E, Le annir NM, Siefker-Radtke AO, Gao J, Roszik J, Subbiah VH, Shah AY, Campbell MT, T. Outcomes and the impact of genomic characteristics on patients with metastatic urothelial carcinoma enrolled in early phase trials. ASCO Annual Meeting 2020, 2020. PMID: None.
49. Huey R, George G, Phillips P, White R, Fu S, Janku F, Karp DD, Naing A, Piha-Paul SA, Subbiah V, Tsimberidou AM, Pant S, Yap TA, Rodon Ahnert J, Meric-Bernstam F, Shih YT, Hong DS. Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials. ASCO Annual Meeting 2020, 2020. PMID: None.
50. Murthy R, Sheth R, Subbiah V, Janku F, Naing A, Rodon J, Yap TA, Diab A, Patel SP, Tam A, Gupta S, Meric-Bernstam F. Intratunor immunotherapy utilizing real time radiological image guidance: Early experience from a tertiary cancer center. ASCO Annual Meeting 2020, 2020. PMID: None.
51. Yap TA, Lakhani NJ, Araujo DV, Rodon Ahnert J, Chandana SR, Sharma M, Denis J, Gruosso T, Tremblay G, O’Connor M, Ghosh R, Sinclair S, Wood DL, Nadler PI, Siu LL. AVID200, firstin-class TGF-beta 1 and 3 selective and potent inhibitor: Safety and biomarker results of a phase I immunotherapy dose-escalation study in patients with advances solids tumors. ASCO Annual Meeting 2020, 2020. PMID: None.
52. Avila M, Wathoo C, Zeng J, Anderson C, Yuan Y, Yap TA, Rodon Ahnert J, Meric-Bernstam F. Variety of clinical trial enrollment by actionable tumor suppressor genotype. ASCO Annual Meeting 2020, 2020. PMID: None.
53. Subbiah IM, Buzdar A, Ileana Dumbrava EE, Fu S, Janku F, Karp DD, Naing A, Pant S, Rodon J, Tsimberidou AM, Yap TA, Subbiah V, Meric-Bernstam F, Hong DS. Investigating the disparate enrollment of older adults on phase I clinical trials: evolving participation patterns of patients 65 years and older w advanced cancer on phase I trials. ASCO Annual Meeting 2020, 2020. PMID: None.
54. Garmezy B, Gheeya JS, Thein KZ, Pilie PG, Wang W, Rodon Ahnert J, Shaw KR, MericBernstam F, Yap TA. Corrleation of pathogenic POLE mutations with clinical benefit to immune checkpoint inhibitor therapy. ASCO Annual Meeting 2020, 2020. PMID: None.
55. Hahn AW, Alhalabi O, Meric-Bernstam F, Naing A, Jonasch E, Msaouel P, Piha-Paul SA, Hong DS, Pant S, Yap TA, Campbell E, Le H, Tannir NM, Roszik J, Subbiah V. Phase I clinical trials as a therapeutic option for patients with metastatic renal cell carcinoma (mRCC). ASCO Annual Meeting 2020, 2020. PMID: None.
56. Yap TA, Araujo D, Wood D, Denis JF, O'Connor-McCourte M, Ghosh R, Sinclair S, Nadler P, Siu L, Lakhani N. AVID200, first-in-class TGF-beta1 and beta3 selective inhibitor: Results of a Phase 1 monotherapy dose escalation study in solid tumors and evidence of target engagement in patients. SITC 2019, 2019. PMID: None.
57. Hedge A, Jayaprakash P, Sumner E, Nguyen D, Zain H, Piha-Paul SA, Karp D, Rodon JA, Pant S, Fu S, Ileana Dumbrava EE, Yap TA, Subbiah V, Bhosale P, Higgins JP, Williams ET, Wilson TF, Meric-Bernstam F, Curran MA, Hong DS. A Phase 1 Dose Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies. SITC 2019, 2019. PMID: None.
58. Pilie PG, Tang Z, Park S, Wu C, Dong Z, Yap TA, Corn P, Thompson. Inhibitors of AtaxiaTelangiectasia Related (ATR) protein lead to innate immune pathway activation and enhanced response to immune therapy in prostate cancer. SITC 2019, 2019. PMID: None.
59. Yu D, Szpurka AM, Carlsen M, HOllebecque A, Chung HC, Patnaik A, Bendell J, Italiano A, Bang YJ, Lin CC, Butler MO, Yap TA, Joes De Miguel M, Macheils JP, Peeters M, Su WC, Morena V, Zhao Y, Rasmussen E, Xu X. The positive correlation between baseline absolute eosinophil count (AEC) in blood and clinical benefit to PD-(L)1 inhibition monotherapy. SITC 2019, 2019. PMID: None.
60. Evans K, Moulder S, Yuca E, Scott S, Arango N, Shariati M, Vellano C, Saridogan T, Zheng X, Gonzalez-Angulo A, Zhao M, Su X, Tapia C, Chen K, Akcakanat A, Perou C, Lim B, Tripahty D, Yap TA, Di Francesco M, Draetta G, Jones P, Marszalek J, Meric-Bernstam F. Oxidative phosphorylation is a metabolic vulnerability in chemotherapy resistant triple negative breast cancer. AACR-NCI-EORTC Conference 2019, 2019. PMID: None.
61. Coyne GO, Yap TA, Moore N, Mittra A, Takebe N, Juwara L, Khan S, Ileana Dumbrava EE, Streicher H, Pieakarz R, Sharon E, Meric-Bernstam F, Parchment R, Navas T, Fung K, Mitchell J, Fino K, Montez S, Doyle A, Rubinstein L, Doroshow J, Chen A. Phase IB combination study of copanlisib and nivolumab in advanced solid tumors and lymphomas. AACR-NCI-EORTC Conference 2019, 2019. PMID: None.
62. Naing A, Meric-Bernstam F, Karp D, Rodon JA, Piha-Paul SA, Subbiah V, Hong DS, Pant S, Fu S, Janku F, Yap TA, Tsimberidou AM, Ileana Dumbrava EE, Colen RR, Hess KR, Campbell, MT, Tu S, Jimenez C, Habra MA, Varadhachary GR. Pembrolizumab in Advanced Rare Cancers. ESMO Congress 2019, 2019. PMID: None.
63. Reilley M, Tsimberidou AP, Piha-Paul SA, Yap TA, Fu S, Naing A, Rodon J, Nguyen LM, Ager C, Meng M, Jayaprakash P, Schmidt M, Baumann M, Meric-Bernstam F, Curran MA, Hong DS. Phase 1 trial of TLR9 agonist lefitolimod in combination with CTLA-4 checkpoint inhibitor ipilimumab in advanced tumors. ASCO 2019 Annual Meeting, 2019. PMID: None.
64. Yap TA, Rodon JA, Piha-Paul SA, Siqing F, Janku F, Karp DD, Naing A, Dumbrava EEI, Shubham P, Subbiah V, Tsimberidou AM, Hong DS, Rose KM, Xu Q, Vellano CP, Mahendra M, Jones P, di Francesco ME, Marszalek JR, Meric-Bernstam F. Phase I trial of IACS-010759 (IACS), a potent, selective inhibitor of complex I of the mitochondrial electron transport chain, in patients (pts) with advanced solid tumors. ASCO 2019 Annual Meeting, 2019. PMID: None.
65. Yap TA. Partners With PARP?. ASCO 2019 Annual Meeting, 2019. PMID: None.
66. Yap TA, Papadopoulos KP, LoRusso P, Wong DJL, Hu-Lieskovan S, Holz JB, Team FS. A first-in-human phase I study of FS118, an anti-LAG-3/PD-L1 bispecific antibody in patients with solid tumors that have progressed on prior PD-1/PD-L1 therapy. ASCO 2019 Annual Meeting, 2019. PMID: None.
67. Pant S, Mulder I, Shah AY, Msaouel P, Altan M, Weinberg J, Stevenson A, Meric-BernstaM F, Yap TA, Subbiah V, Rodon JA. A phase I/II study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients who have progressed on prior anti-PD-1 therapy. ASCO 2019 Annual Meeting, 2019. PMID: None.
68. Huey R, George G, Phillips P, White R, Fu S, Karp DD, Naing A, Piha-Paul SA, Subbiah V, Tsimberidou AM, Pant S, Yap TA, Rodon JA, Meric-Bernstam F, Shih YT, Hong DS. Out of pocket costs and financial toxicity experienced by patients in early phase clinical trials. ASCO 2019 Annual Meeting, 2019. PMID: None.
69. Lopez JS, SelviMiralles M, Ameratunga M, Minchom A, Pascual J, Banerji U, Bye H, Raynaud FI, Swales KE, Malia J, Hubank M, Garcia-Murillas I, Parmar M, Ward SE, Finneran L, Hall E, Turner AJ, de Bono JS, Yap TA, Turner NC. PIPA: A phase Ib study of selective ß-isoform sparing phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (T) plus palbociclib (P) in patients (pts) with advanced solid cancers—Safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the doublet combination. ASCO 2019 Annual Meeting, 2019. PMID: None.
70. Pestana RC, Subbiah IM, Hess KR, Le H, Liu S, Beltran K, Harrison H, Bryant A, Eshon J, Yap TA, Pant S, Naing A, Hong DS, Meric-Bernstam F, Subbiah V. Re-evaluating eligibility criteria: Analysis of factors leading to nonparticipation and outcomes of patients (pt) with advanced cancer who signed consent but were not treated in early-phase immunotherapy (IO) trials. ASCO 2019 Annual Meeting, 2019. PMID: None.
71. Gabrail NY, Bessudo A, Hamilton EP, Sachdev JC, Patel MR, Rodon JA, Evilevitch L, Duncan M, Guo W, Lu S, Dezube BJ, Yap TA. IOLite: Multipart, phase 1b, dose-finding study of the PD-1 inhibitor dostarlimab in combination with the PARP inhibitor niraparib ± bevacizumab (bev), or with platinum-based chemotherapy ± bev for advanced cancer. ASCO 2019 Annual Meeting, 2019. PMID: None.
72. Hyman DM, Zelnak AB, Bauer TM, Ulahanan SV, Ford JM, Cesari R, Hoyle M, Chappey C, Stewart R, Conte U, Yap TA. JAVELIN BRCA/ATM: A phase 2 trial of avelumab (anti–PD-L1) plus talazoparib (PARP inhibitor) in patients with advanced solid tumors with a BRCA1/2 or ATM defect. ASCO 2019 Annual Meeting, 2019. PMID: None.
73. de Bono JS, Peng Tan DS, Caldwell R, Terbuch A, Goh BC, Heong V, NMd H, s B, Hong DS, Meric-Bernstam F, Bordia S, Liu L, Wilkinson G, Hreiki J, Wengner A, Fischer K, Boix O, Lagkadinou E, Plummer E, Yap TA. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. ASCO 2019 Annual Meeting, 2019. PMID: None.
74. Papadopoulos KP, Lakhani NJ, Johnson ML, Park H, Wang D, Yap TA, Dowlati A, Maki RG, Lynce F, Ulahannan SV, Kelly K, Sims TN, Bredlau AL, Bramble D, Gonzalez Ortiz A, Zhu M, Chen H, Karasarides M, Kroog G. First-in-human study of REGN3767 (R3767), a human LAG- 3 monoclonal antibody (mAb), ± cemiplimab in patients (pts) with advanced malignancies. ASCO 2019 Annual Meeting, 2019. PMID: None.
75. Kurnit KC, Meri-Bernstam F, Hess K, Coleman RL, Bhosale P, Savelieva K, Janku F, Hong D, Naing A, Pant S, Rodon J, Yap TA, Sood AK, Soliman PT, Gershenson DM, Mills GB, Westin SN. Phase I dose escalation of olaparib (PARP inhibitor) and selumetinib (MEK Inhibitor) combination in solid tumors with Ras pathway alterations. AACR 2019 Annual Meeting, 2019. PMID: None.
76. Yap TA, Gainor JF, Callahan MK, Falchook GS, Pachynski RK, LoRusso P, Kummar S, Gibney GT, Burris HA, Tykodi SS, Rahma OE, Seiwert T, Papadopoulos KP, Hooper E, Harvey CJ, Hanson A, Lacey S, McComb R, Hart C, Laken H, McClure AT, Trehu E. Improved progressionfree and overall survival (PFS/OS) in patients (pts) with emergence of JTX-2011 associated biomarker (ICOS high CD4 T cells) on the ICONIC trial. AACR 2019 Annual Meeting, 2019. PMID: None.
77. Yap TA. First-in-human phase 1 dose-escalation trial of the potent and selective next generation transforming growth factor-β receptor type 1 (TGF-βR1) inhibitor LY3200882 in patients with advanced cancers. None, 2018. PMID: None.
78. Yap TA. JAVELIN PARP Medley: a phase 1b/2 study of avelumab (anti–PD-L1) plus talazoparib in locally advanced or metastatic solid tumors. ESMO 2018 Congress, 2018. PMID: None.
79. Papadopoulos KP, Lakhani NJ, Johnson ML, Park H, Wang D, Yap TA, Moore KN, Sims TN, Emeremni C, Karasarides M, Kroog GS. A study of REGN3767, an anti-LAG-3 antibody, alone and in combination with cemiplimab (REGN2810), an anti-PD1 antibody, in advanced cancers. ASCO 2018 Annual Meeting, 2018. PMID: None.
80. Kheder E, Hess KR, Xing Y, Cortez MA, Subbiah V, Janku F, Fu S, Naing A, Karp DD, Piha-Paul SA, Yap TA, Pant S, Rodon Ahnert J, Tawbi HA, Welsh JW, Meric-Bernstam F, Hong DS. TP53 mutations and programmed cell death ligand-1 expression in solid tumors: Associations with clinical factors and outcomes. ASCO 2018 Annual meeting, 2018. PMID: None.
81. Pilie PG, Peterson CB, Peng Y, Zhou L, Yap TA, Peng G, Jonasch E. Functional biomarkers of homologous repair (HR) deficiency to guide novel DNA damage response targeted therapy in clear cell renal cell carcinoma. ASCO 2018 Annual Meeting, 2018. PMID: None.
82. Yap TA, Sahebjam S, Hong DS, Chiu VK, Yilmaz E, Efuni S, Grebennik DO, Collaku A, Ogunmefun E, Liu Y, Tayama T, Latek RR, Rixe O. First-in-human study of KHK2455, a long-acting, potent and selective indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor, in combination with mogamulizumab (Moga), an anti-CCR4 monoclonal antibody, in patients (pts) with advanced solid tumors. ASCO 2018 Annual Meeting, 2018. PMID: None.
83. Yap TA, Burris HA, Kummar S, Falchook GS, Pachynski RK, LoRusso P, Tykodi SS, Gibney GT, Gainor JF, Rahma OE, Seiwert TY, Meric-Bernstam F, Blum Murphy MA, Keating Litton J, Diament Hooper EM, Hirsch HA, Harvey C, Clancy M, McClure T, Callahan MK. ICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX-2011 +/- nivolumab (nivo) in patients (pts) with advanced cancers. ASCO 2018 Annual Meeting, 2018. PMID: None.
84. Piha-Paul SA, Fu S, Hong DS, Janku F, Karp DD, Naing A, Pant S, Rodon Ahnert J, Subbiah V, Tsimberidou AM, Yap TA, Meric-Bernstam F. Phase I study of the pan-HER inhibitor neratinib given in combination with everolimus, palbociclib or trametinib in advanced cancer subjects with EGFR mutation/amplification, HER2 mutation/amplification or HER3/4 mutation. ASCO 2018 Annual Meeting, 2018. PMID: None.
85. Patnaik A, Y-J B, Chung HC, de Miguel Luken MJ, Yap TA, Hu L, Szpurka AM, Yu D, Chatterjee A, Nanda S, Vangerow B, Koneru M, Bendell J. Interim safety and clinical activity in patients (pts) with advanced refractory solid tumors from a phase Ia/b study investigating the novel anti-PD-L1 antibody (LY3300054) administered alone or in combination with other agents. AACR 2018 Annual Meeting, 2018. PMID: None.
86. Okeley NM, Heiser RA, Zeng W, Hengel SM, Wall J, Haughney PC, Yap TA, Robert F, Sanborn RE, Burris H, Chow LQM, Do KT, Gutierrez M, Reckamp K, Weise A, Camidge DR, Strickler J, Steuer C, Wang Z, O'Meara MM, Alley SC, Gardai SJ. SGN-2FF: A small-molecule inhibitor of fucosylation modulates immune cell activity in preclinical models and demonstrates pharmacodynamic activity in early phase 1 analysis. AACR 2018 Annual Meeting, 2018. PMID: None.
87. Pant S, Subbiah V, Rodon J, Janku F, Hong DS, Karp D, Piha-Paul SA, Tsimberidou AM, Naing A, Fu S, Savage RE, Chai F, Yu Y, Schwartz B, Meric-Bernstam F, Yap T. Results of a phase I dose escalation study of ARQ 751 in adult subjects with advanced solid tumors with AKT1, 2, 3 genetic alterations, activating PI3K mutations, PTEN-null, or other known actionable PTEN mutations. AACR 2018 Annual Meeting, 2018. PMID: None.
88. Harris SJ, de Miguel Luken MJ, Roda Perez D, Perez Lopez R, Parmar M, Prathapan V, Hassam H, Turner AJ, Serrano Fandos S, Hall E, Tovey H, Tunariu N, Lopez JS, Yap TA, De Bono JS, Banerji U. Updated efficacy and safety results from the phase I study of intermittent dosing of the dual MEK/RAF inhibitor, RO5126766 in patients (pts) with RAS/RAF mutated advanced solid tumours. J Clin Oncol 34, 2016. PMID: None.
89. Harris SJ, O'Carrigan B, Lopez SJ, Bhosle J, Banerji U, Popat S, De Bono JS, O'Brien MER, Yap TA. Clinical outcomes of advanced small cell lung cancer patients (SCLC pts) on phase I (Ph I) trials in the Drug Development Unit (DDU) at the Royal Marsden Hospital (RMH). J Clin Oncol 34, 2016. PMID: None.
90. Yap TA, Krebs MG, Postel-Vinay S, Bang YJ, El-Khoueiry A, Abida W, Harrington K, Sundar R, Carter L, Castanon-Alvarez E, Im SA, Berges A, Khan M, Stephens C, Ross G, Soria JC. Phase I modular study of AZD6738, a novel oral, potent and selective ataxia telangiectasia Rad3-related (ATR) inhibitor in combination (combo) with carboplatin, olaparib or durvalumab in patients (pts) with advanced cancers. 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 2016, 2016. PMID: None.
91. Ahmad Z, Fraser-Fish J, Kumar R, Ebbs B, Fowler G, Flohr P, Crespo M, Ahmad M, Popat S, Bhosle J, Banerji U, O'Brien M, de Bono J, Yap TA. Molecular characterization of PD-L1 status on circulating tumour cells (CTCs) isolated from patients with advanced cancers. NCRI Cancer Conference 2016, 2016. PMID: None.
92. Fraser-Fish J, Ahmad Z, Kumar R, Ebbs B, Fowler G, Flohr P, Crespo M, Ahmed M, Popat S, Bhosle J, Banerji U, O’Brien M, De Bono JS, Yap TA. Molecular characterization of PDL1 status of circulating tumor cells (CTCs) isolated with a novel label-free inertial microfluidic system from patients (pts) with advanced cancers. ESMO 2016 Congress, 2016. PMID: None.
93. Michalarea V, Constantinidou A, Guardascione M, Diamantis N, Perez R, Rihawi K, Geuna E, Lopez J, Kaye SB, Yap TA, De Bono JS, Banerji U, Molife LR, Tunariu N. Ultrasound guided biopsies in phase I trials: Single center experience of 350 consecutive cases. J Clin Oncol 34, 2016. PMID: None.
94. Gao FF, O'Brien M, Sarker, D Bhosle J, Yap TA, Uttenreuther-Fischer MM, Pemberton K, Goeldner RG, Wiebe S, De Bono JS, Spicer JF. A phase I study of afatinib combined with carboplatin or carboplatin plus paclitaxel in patients (pts) with advanced solid tumors. J Clin Oncol 34, 2016. PMID: None.
95. Sundar R, Custodio A, Lim J, Chenard-Poirier M, Collins D, Kaye S, Yap TA, Banerji U, Lopez J, De Bono JS. Clinical outcome of patients with advanced biliary tract cancer in a dedicated phase 1 unit. ESMO 2016 Congress, 2016. PMID: None.
96. Yap TA, Winter JN, Leonard JP, Ribrag, V, Constantinidou A, Giulino-Roth L, Michot JM, Khan TA, Horner T, Carver J, Dumetrescu TP, He Z, McCabe MT, Creasy CL, Arindam Dhar A, Carpenter C, Johnson PM. A Phase I Study of GSK2816126, an Enhancer of Zeste Homolog 2 (EZH2) Inhibitor, in Patients (pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Other Non-Hodgkin Lymphomas (NHL), Transformed Follicular Lymphoma (tFL), Solid Tumors and Multiple Myeloma (MM). ASH 58th Annual Meeting 2016, 2016. PMID: None.
97. Billingham L, Dee Wherton D, Llewellyn L, Brown S, Johnson S, Fletcher P, Mulatero C, Yap TA, Summers Y, Spicer J, Sharpe R, Popat S, Middleton G. National Lung Matrix Trial: successful implementation of a phase II umbrella trial testing multiple genetic-marker-directed drugs in advanced non-small cell lung cancer. NCRI Cancer Conference 2016, 2016. PMID: None.
98. Coleman N, Michalarea V, Alken SP, Rihawi K, Greenwood K, Perez Lopez R, Tunariu N, Yap TA, Banerji U, De Bono JS, Welsh L, Molife LR, Saran F, Lopez J. Safety, efficacy and survival of patients (pts) with primary CNS tumors in phase 1 (Ph1) trials: A 12-year single institution experience. J Clin Oncol 34, 2016. PMID: None.
99. O'Carrigan B, de Miguel Luken MJ, Papadatos-Pastos D, Brown J, Tunariu N, Perez Lopez R, Ganegoda M, Riisnaes R, Figueiredo I, Carreira S, Hare B, Yang F, McDermott K, Penney MS, Pollard J, Lopez JS, Banerji U, De Bono JS, Fields SZ, Yap TA. Phase I trial of a first-in-class ATR inhibitor VX-970 as monotherapy (mono) or in combination (combo) with carboplatin (CP) incorporating pharmacodynamics (PD) studies. J Clin Oncol 34, 2016. PMID: None.
100. Diamantis N, Harris SJ, Constantinidou A, Vasiliki Michalarea V, Fontes MS, de Miguel Luken MJ, Avaiya TL, Petruckevitch A, Flohr D, Hanwell J, Papadatos-Pastos D, Lopez J, Yap TA, De Bono JS, Banerji U. Incidence, severity and factors associated with diarrhoea in phase I oncology studies: experience of 1002 consecutive cases. J Clin Oncol 34, 2016. PMID: None.
101. Krebs MG, Spicer J, Steele JN, Talbot DC, Brada M, Wilson RH, Jones R, Basu B, Dawes JC, Parmar M, Purchase B, Turner AJ, Hall E, Tovey H, Banerji U, Yap TA. TAX-TORC: The Novel Combination of Weekly Paclitaxel and the Dual mTORC1/2 Inhibitor AZD2014 for the Treatment of Squamous NSCLC. 17th World Conference on Lung Cancer, 2016. PMID: None.
102. O'Carrigan B, Jalil A, Papadatos-Pastos D, Harris SJ, Lopez J, Banerji U, De Bono JS, Yap TA. Target-based therapeutic matching of phase I trials in patients with advanced breast cancer (BC pts) in the Royal Marsden Hospital Drug Development Unit (RMH DDU). J Clin Oncol 34, 2016. PMID: None.
103. Yap TA, Johnson PWM, Winter J, Leonard J, Giulino-Roth L, Horner T, Radswillas K, Carver J, Dhar A. A phase I, open-label study of GSK2816126, an enhancer of zeste homolog 2 (EZH2) inhibitor, in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (tFL), other non-Hodgkin’s lymphomas (NHL), multiple myeloma (MM) and solid tumor. J Clin Oncol 34, 2016. PMID: None.
104. Middleton G, Popat S, Walker I, Mulatero C, Spicer J, Summers Y, Yap TA, Crack LR, Billingham LJ. The National Lung Matrix Trial: Multi-Drug, Genetic Marker-Directed, Multi-Arm Phase II Trial in Non-Small Cell Lung Cancer IASLC. IASLC. e-Pub 2015. PMID: None.
105. Papadatos-Pastos D, Roda D, De Miguel Luken MJ, Michalarea V, Lima J, Diamantis N, Capelan M, Jalil A, Bodla S, Bhosle J, Molife R, O’Brien M, Banerji U, Popat S, Yap TA. Clinical outcome and prognostic factors for advanced malignant mesothelioma (MM) patients (pts) treated on phase I trials. IASLC 2015. e-Pub 2015. PMID: None.
106. George A, Michalarea V, Rafii S, Michie CO, Wong M, Bowen R, Han LY, Rallis G, Banerji U, Kristeleit R, de Bono JS, Banerjee S, Gore M, Kaye SB, Yap TA. Clinical outcomes in advanced cervical cancer (CC) and endometrial cancer (EC) patients (pts) treated in phase I trials of novel molecularly targeted agents (MTAs). J Clin Oncol 33(15S), 2015. PMID: None.
107. Papadatos-Pastos D, Kumar R, Yap TA, Ruddle R, Decordova S, Jones P, Halbert G, Garrett MD, McLeod R, Backholer Z, Swales KE, Raynaud FI, de Bono JS, Banerji U. A first-in-human study of the dual ROCK I/II inhibitor, AT13148, in patients with advanced cancers. J Clin Oncol 33(15S), 2015. PMID: None.
108. de Miguel Luken MJ, Roda D, Perez Lopez R, Jimenez B, Hassam H, Sathiyayogan N, Parmar M, Turner AJ, Hall E, Tunariu N, Molife LR, Yap TA, de Bono JS, Banerji U. A pharmacokinetic and pharmacodynamic biomarker-driven phase I study of intermittent, low dose intensity schedules of the dual MEK/RAF inhibitor, RO5126766 in patients with advanced solid tumors. None 33(15S), 2015. PMID: None.
109. Rafii S, Gourley C, Ang JE, Kumar R, Geuna E, Rye T, Ashcroft L, Powell B, Shapira-Frommer R, Friedlander M, Chen LM, Matulonis U, Kaufman B, De Greve J, Oza AM, Banerjee S, Gore ME, Molife LR, Kaye SB, Yap TA. What clinical factors influence advanced BRCA1/2 mutant ovarian cancer patient outcomes to poly(ADP-ribose) polymerase inhibitor treatment?. J Clin Oncol 33(15s), 2015. PMID: None.
110. 29Michalarea V, de Miguel Luken MJ, Diamantis N, Garg A, Maubon L, Yap TA, Molife LR, de Bono JS, Ursell P, Banerji U. Ocular toxicity with MEK inhibitors in phase I trials: A single centre experience across six clinical trials. J Clin Oncol 33(15S), 2015. PMID: None.
111. Yap T, Williamson S, Beggs A, Creedon H Hargreaves C, Norris L, Richman S, Romero D, Roxburgh T, Savage K, Turkington R, Walter H, Fairbairn E. Training the next generation of cancer research leaders: development of the Experimental Cancer Medicines Centers (ECMC) Junior Investigator Network Group (JING). NCRI Cancer Conference. e-Pub 2014. PMID: None.
112. Yap TA, Ahmad Z, Fraser-Fish J, de Bono JS. Assessment and validation of a novel high throughput label-free microfluidic-based circulating tumor cell (CTC) platform. Prostate Cancer Foundation Annual Retreat. e-Pub 2014. PMID: None.
113. Roda D, Wong HH, Geuna E, Rafii S, Ruddle R, Hayes A, Swales K, Stimpson S, Sathiyayogan N, Tunariu N, Turner A, Hall E, Yap TA, Banerjee S, O'Brien M, Molife LR, Kaye S, de Bono J, Basu B, Banerji U. TAX-TORC: A phase I trial of the combination of AZD2014 (dual mTORC1/mTORC2 inhibitor) and weekly paclitaxel in patients with solid tumors. J Clin Oncol 32(15S), 2014. PMID: None.
114. Geuna E, Roda D, Rafii S, Jimenez B, Capelan M, Rihawi K, Yap TA, Kaye S, de Bono JS, Molife LR, Banerji U. Complications of hyperglycemia in phase 1 trials targeting the PI3K-AKT-mTOR pathway. J Clin Oncol 32(15S), 2014. PMID: None.
115. Rafii S, Roda D, Geuna E, Jimenez B, Rihawi K, Capelan M, Yap TA, Kaye S, Molife LR, de Bono J, Banerji U. A study of risk of infection with drugs targeting the PI3K, AKT, and mTOR pathway. J Clin Oncol 32(15S), 2014. PMID: None.
116. Frenel JS, Carreira S, Goodall J, Roda D, Smith A, Mateo J, Ong M, Gasi-Tandefelt D, Yap TA, Attard G, Figueiredo I, Rodrigues D, Flohr P, Molife LR, Kaye SB, Banerji U, de Bono SB. Targeted deep sequencing from circulating plasma DNA as a multipurpose biomarker in patients referred for phase I trials. J Clin Oncol 32(15S), 2014. PMID: None.
117. Kumar R, Mateo J, Smith A, Khan K, Ruddle R, Swales K, Decordova S, Backholer Z, Jones P, Tran C, Seeramreddi S, McLeod R, Yap TA, Raynaud F, Garrett M, Banerji U. TAX-TORC: A phase I trial of the combination of AZD2014 (dual mTORC1/mTORC2 inhibitor) and weekly paclitaxel in patients with solid tumors. J Clin Oncol 32(15S), 2014. PMID: None.
118. Yap TA, George A, Michie C, Wong M, Bowen R, Rafii S, Michalarea V, van Hagen T, Han L, Rallis G, Molife LR, Banerji U, Kristeleit R, Banerjee S, de Bono JS, Gore ME, Kaye SB. What factors influence advanced ovarian cancer patient outcomes to phase I trial treatments?. J Clin Oncol 32(15S), 2014. PMID: None.
119. Mateo J, De Bono JS, Ramanathan RK, Lustberg MB, Zivi A, Basset D, Ng M, Young A, Garrett M, Decordova S, Raynaud F, Yap TA, Zukiwski AA, Proniuk S, Shapiro CL. A first-in-human phase I trial of AR-12, a PDK-1 inhibitor, in patients with solid tumors. J Clin Oncol 31(15S), 2013. PMID: None.
120. Khan KH, Young A, Mateo J, Tunariu N, Yap TA, Tan D, Mansfield D, Wong M, Riisnaes R, Harrington KJ, De Bono JS. Phase I clinical trial of a genetically modified and oncolytic vaccinia virus GL-ONC1 with green fluorescent protein imaging. J Clin Oncol 31(15S), 2013. PMID: None.
121. Mateo J, Ong M, Pope L, Cassidy AM, Yap TA, Perkins G, Riisnaes R, Flohr P, Thway K, Gonzalez M, Saeed S, Young AM, Toloui HN, Khan K, Moran K, Ng M, Molife LR, Banerji U, Kaye SB, de Bono JS. Correlation of oncogenic mutations in circulating cell-free DNA (cfDNA) and tumor tissue through a multiplex sequencing platform in patients under consideration for phase I trials. J Clin Oncol 30(15S), 2012. PMID: None.
122. Ong M, Mateo J, Pope L, Cassidy AM, Yap TA, Perkins G, Riisnaes R, Flohr P, Thway K, Saeed S, Denholm KA, Jaime JC, Biondo A, Molife LR, Kaye SB, Banerji U, de Bono JS. Prospective study of oncogenic mutations in circulating cell-free DNA (cfDNA) using a multiplex sequencing platform for patient (pt) allocation to phase I clinical trials. J Clin Oncol 30(15S), 2012. PMID: None.
123. Ang JE, Gourley C, High HA, Shapira-Frommer R, Powell CB, Castonguay V, de Greve J, Yap TA, Fong PC, Olmos D, Banerjee SN, Chen LM, Friedlander M, Kaufman B, Oza AM, de Bono JS, Gore ME, Kaye SB. Use of chemotherapy (CT) in BRCA1/2-deficient ovarian cancer (BDOC) patients (pts) with poly-ADP-ribose polymerase inhibitor (PARPi) resistance: A multi-institutional study. J Clin Oncol 30(15S), 2012. PMID: None.
124. Jaime JC, Young AM, Mateo J, Yap TA, Denholm KA, Shah KJ, Tunariu N, Sassi S, Karapanegiotou L, Mansfield D, Molife LR, Harrington KJ, de Bono JS. Phase I clinical trial of a genetically modified and oncolytic vaccinia virus GL-ONC1 with green fluorescent protein imaging. J Clin Oncol, 2012. PMID: None.
125. Yap TA Yan L, Patnaik A, Olmos D, Fearen I, Baird RD, Papadopoulos KP, Tunariu N, Biondo A, Keilhack H, Delgado LM, Taylor A, Blackman SC, Carpenter CL, Decordova S, Heaton S, Garrett MD, Sullivan D, De Bono JS, Tolcher W. Final results of a translational phase l study assessing a QOD schedule of the potent AKT inhibitor MK-2206 incorporating predictive, pharmacodynamic (PD), and functional imaging biomarkers. J Clin Oncol 29(15S), 2011. PMID: None.
126. Tan DSP, Yap TA, Hutka MM, Roxburgh P, Grzybowska E, Gourley C, Gore ME, Kaye SB. Implications of BRCA1 and BRCA2 mutations on taxane sensitivity in patients (pts) with advanced ovarian cancer. J Clin Oncol 29(15S), 2011. PMID: None.
127. Pedersen JV, Karapanagiotou EM, Biondo A, Tunariu N, Puglisi M, Denholm KA, Sassi S, Mansfield D, Yap TA, de Bono JS, Harrington KJ. A phase I clinical trial of a genetically modified and imageable oncolytic vaccinia virus GL-ONC1 with clinical green fluorescent protein (GFP) imaging. J Clin Oncol 29(15S), 2011. PMID: None.
128. Yap TA, Patnaik A, Fearen I, Olmos D, Papadopoulos K, Tunariu N, Sullivan D, Yan L, de Bono JS, Tolcher AW. A translational biomarker study of MK2206 (MK), a potent allosteric AKT inhibitor demonstrating profound target and pathway inhibition. ASCO-NCI-EORTC 2010 Molecular Markers in Cancer, 2010. PMID: None.
129. Pederson JV, Karapanagiotou L, Alam S, Puglisi M, Britton L, Sassi S, Mansfield D, Yap T, De-Bono J, Harrington K. Preliminary results of a Phase 1 study of intravenous administration of GL-ONC1 Vaccinia virus in patients with advanced solid cancer with real time imaging. NCRI Meeting. e-Pub 2010. PMID: None.
130. Papadatos-Pastos D, Baird R, d O, Sandhu S, Massard C, Dukes J, Pope L, Grainger P, Yap T, De-Bono, J. Baseline circulating tumour cell (CTC) counts enhance the performance of the Royal Marsden Hospital (RMH) prognostic score to optimize patient selection for phase 1 clinical trials. NCRI Cancer Conference. e-Pub 2010. PMID: None.
131. Yap TA, Patnaik A, Fearen I, Olmos D, Papadopoulos K, Tunariu N, Sullivan D, Yan L, de Bono JS, Tolcher AW. First-in-class phase I trial of a selective Akt inhibitor, MK2206, evaluating alternate day and once weekly doses in advanced cancer patients with evidence of target modulation and antitumor activity. J Clin Oncol 29(15S), 2010. PMID: None.
132. Ang J, Yap TA, Fong P, Carden C, Tan DS, Carmichael J, de Bono JS, Gore M, Kaye SB. Preliminary experience with the use of chemotherapy following treatment with olaparib, a poly(ADP-ribose) polymerase inhibitor, in patients with BRCA1/2-deficient ovarian cancer. J Clin Oncol 28(15s), 2010. PMID: None.
133. Tan D, Lolkema M, Harrington K, Forster M, Evans J, Arkenau HT, Roxburgh P, Morrison R, Kapawa J, Roulstone V, Coffey M, Alam S, Brunetto A, Yap TA, Mettinger K, de Bono JS. A phase-I study of the combination of intravenous reovirus (REOLYSIN) and gemcitabine in patients with advanced cancer. NCRI Cancer Conference. e-Pub 2009. PMID: None.
134. Alam S, Carden C, Langham M, Frentzas S, Dolly S, Sandhu S, Kristeleit R, Yap TA, Casamayor I, Matthews T, Stephens AW, Poondru S, Kim E, Kaye SB. Preliminary activity in adrenocortical tumour (ACC) in phase I dose escalation study of intermittent oral dosing of OSI-906, a small molecule insulin like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor in patients with advanced solid tumours. NCRI Cancer Conference. e-Pub 2009. PMID: None.
135. Brunetto AT, Kristeleit R, Tan D, Yap TA, Alam S, Dolly S, Olmos D, Fong P, Molife R, Harris T, Van Besterveldt L, Fourneau N, Hellemans P, De-Bono JS, Venugopal B, Evans J. A first in human phase I study of JNJ26481585, a novel oral histone deacetylase inhibitor (HDACi), in patients with advanced solid tumours: early evidence of anti-tumour activity. NCRI Cancer Conference. e-Pub 2009. PMID: None.
136. Forster M, Olmos D, Frentzas S, Sandhu S, Yap TA, Tan D, Barriuso J, Wright M, Morris Groves M, Reardon D, Curtis M, Hodge J, Suttle B, Ma B, Lager J, de Bono JS. Pazopanib and lapatinib in patients with relapsed malignant glioma: Phase I/II study. NCRI Cancer Conference. e-Pub 2009. PMID: None.
137. Yap TA, Alam S, Lolkema M, Tan DS, Forster M, Dolly S, Carden CP, Sandhu S, Fong P, Little A, Patnaik A, Papadopoulos K, Tromp B, Puchalski T, Berns B, Tolcher A, de Bono JS. First-in-man, pharmacokinetic and pharmacodynamic phase I trial of a human monoclonal antibody CNTO888 to CC-Chemokine Ligand 2 (CCL2/MCP-1) in patients with solid tumours. NCRI Cancer Conference. e-Pub 2009. PMID: None.
138. Sandhu S, Yap TA, Tunariu N, Lolkema M, Tan DS, Brunetto AT, Kristeleit R, Alam S, Molife R, Kapawa J, Germuska M, Garmey E, Chai F, Li J, Kaye SB, deSouza N, de Bono JS. Pharmacokinetic and pharmacodynamic phase I trial of ARQ197 incorporating dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) studies investigating the antiangiogenic activity of selective c-Met inhibition. NCRI Cancer Conference. e-Pub 2009. PMID: None.
139. Yap TA, Frentzas S, Tunariu N, Barriuso J, Waghorne C, deSouza N, de Bono JS. Final results of a pharmacokinetic and pharmacodynamic phase I trial of ARQ 197 incorporating dynamic contrast-enhanced magnetic resonance imaging studies investigating the antiangiogenic activity of selective c-Met inhibition. J Clin Oncol 27(15s), 2009. PMID: None.
140. Tan D, Brunetto A, Ang J, Olmos D, Frentzas S, Arkenau H, Yap TA, de Bono JS, Kaye SB. Unplanned hospital admissions as an early surrogate indicator of patient attrition in phase I trials. J Clin Oncol 27(15s), 2009. PMID: None.
141. George S, Lal R, Camidge R, Arkenau H, Chick J, Yap TA. Final results of a dose escalation, pharmacokinetic, and pharmacodynamic study of two schedules of OSI-930 in patients with advanced solid tumors. J Clin Oncol 27(15s), 2009. PMID: None.
142. Tolcher AW, Yap TA, Fearen I, Taylor A, Carpenter C, Papadopoulos K, Yan L, de Bono JS. Phase I study of MK-2206 an oral potent allosteric Akt inhibitor in patients with advanced solid tumors. J Clin Oncol 27(15s), 2009. PMID: None.
143. Yap TA, Barriuso J, Frentzas S, Riisnaes R, Clark J, Moreira J, Wright M, Futreal A, Savage R, Chan T, Chai F, de Bono J. Phase I trial of an oral c-Met inhibitor ARQ197, which inhibits tumour c-Met and FAK phosphorylation and has reached maximum tolerated dose in a twice daily dosing schedule. NCRI Cancer Conference, 2008. PMID: None.
144. Boss D, Fong P, Yap TA, Tutt A, Carmichael J, O’Connor M, Schellens J, de Bono J. First in human phase I study of AZD2281, a small molecule inhibitor of PARP. European Assoc for Clin Pharm & Therapeutics (EACPT) Congress, 2008. PMID: None.
145. Yap TA, Harris D, Barriuso J, Wright M, Riisnaes R, Ledaki I, Savage R, de Bono JS. Phase I trial to determine the dose range for the c-Met inhibitor ARQ 197 that inhibits c-Met and FAK phosphorylation, when administered by an oral twice-a-day schedule. J Clin Oncol 26(15S), 2008. PMID: None.
146. de Bono JS, Attard G, Reid A, Parker C, Dowsett M, Molife R, Yap TA, Molina A, Lee G, Dearnaley D. Anti-tumor activity of abiraterone acetate, a CYP17 inhibitor of androgen synthesis, in chemotherapy naive and docetaxel pre-treated castration resistant prostate cancer. J Clin Oncol 26(15S), 2008. PMID: None.
147. Attard G, Reid A, Yap TA, Folkerd E, Clark J, Cooper C, Dowsett M, Lee G, de Bono JS. Predictors of response and pharmacodynamic endpoints in a phase I and pharmacokinetic study of abiraterone acetate in castration-resistant prostate cancer. ASCO Genitourinary Cancers Symposium, 2008. PMID: None.
148. Fong PC, Boss D, Yap TA, Tutt A, Kaye SB, Schellens JH, de Bono JS. A Phase I trial of AZD2281 (KU-0059436), a PARP inhibitor with single agent anticancer activity in patients with BRCA deficient tumours, particularly ovarian cancer. NCRI Cancer Conference. e-Pub 2007. PMID: None.
149. Attard G, Reid A, Yap TA, Molife R, Sinha R, Barrett M, Parker C, Dearnaley D, Raynaud F, Folkerd E, Dowsett M, Lee G, de Bono J. Inhibition of androgen synthesis by selective inhibition of CYP450c17 results in a high response rate in castration-resistant prostate cancer. NCRI Cancer Conference. e-Pub 2007. PMID: None.
150. Haluska P, Shaw H, Molife L, Adjei AA, Yap TA, Roberts ML, Gualberto A, de Bono JS. Phase I dose escalation study of the anti-IGF-1R monoclonal antibody CP-751,871 in patients with refractory solid tumors. J Clin Oncol 25(18S), 2007. PMID: None.
151. Reid AH, Tang A, Spicer J, Gallerani E, Settatree S, Yap TA, Harrison M, de Bono J. An open, PK and mass balance study of 14C-AZD2171, incorporating DCE-CT evaluations. J Clin Oncol, 2007. PMID: None.
152. Kelly WK, Yap T, Lee J, Lassen U, Crowley E, Hawthorne T, Buhl-Jensen P, de Bono J. A phase I study of oral belinostat (PXD101) in patients with advanced solid tumors. None, 2007. PMID: None.
153. Spicer JF, Vidal L, Pandha H, Yap T, White C, Coffey M, Kaye S, Harrington K, de Bono J. Final results of a phase I study of wild-type oncolytic reovirus in patients with advanced cancer. J Clin Oncol, 2007. PMID: None.
154. Gallerani E, Yap TA, Lopez A, de las Heras B, Cortes-Funes H, de Bono J, Paz-Ares L. Phase I study of PM00104, a novel cytotoxic anti-cancer drug, administered to patients with advanced solid tumors or lymphoma. J Clin Oncol 25(18S), 2007. PMID: None.
155. Yap TA, Boss DS, Fong P, Tutt A, Carmichael J, O’Connor MJ, Kaye SB, Schellens J, de Bono JS. First in human phase I PK and PD study of KU-0059436, an inhibitor of Poly ADP-Ribose Polymerase (PARP) in cancer patients, including BRCA1/2 mutation carriers. J Clin Oncol 25(18S), 2007. PMID: None.
156. Attard G, Yap TA, Reid A, Settatree S, Parker C, Raynaud F, Dowsett M, Dearnaley D, de Bono JS. Phase I study of continuous oral dosing of an irreversible CYP450c17 inhibitor, Abiraterone, in castration refractory prostate cancer patients. J Clin Oncol 25(18S), 2007. PMID: None.
157. Yap TA, Attard G, Reid A, Raynaud F, Dowsett M, Dearnaley D, de Bono JS. Abiraterone acetate, an oral irreversible inhibitor of CYP450c17, administered to castration refractory prostate cancer patients is safe and has a high degree of durable antitumor activity. American Urological Association Annual Meeting, 2007. PMID: None.
158. Attard G, Yap TA, Reid A, Parker C, Barrett M, Raynaud F, Dowsett M, Dearnaley D, Lee G, de Bono JS. Activity, toxicity, and effect on steroid precursor levels of abiraterone, an oral irreversible inhibitor of CYP17, in castration refractory prostate cancer. ASCO Prostate Cancer Symposium, 2007. PMID: None.
159. de Bono JS, Attard G, Reid A, Yap TA, Barrett M, Molife R, Parker C, Raynaud F, Dowsett M, Folkerd L, Lee G, Dearnaley D. Abiraterone administered to castration resistant prostate cancer (CRPC) patients is well tolerated and has a high level of antitumor efficacy. AACR Innovations in Prostate Cancer Research Conference, 2006. PMID: None.
160. Fong P, Molife R, Attard G, Yap TA, Vidal L, Digue L, Karavasilis V, Gualberto A, de Bono J. Phase I trial incorporating circulating tumour cells of CP-751,871, a monoclonal antibody against the insulin-like growth factor 1 receptor with docetaxel in cancer patients. Eur J Cancer 4(12S), 2006. PMID: None.
161. Yap TA, Vidal L, Pandha H, Spicer J, Coffey M, Kaye SB, Harrington KJ, De-Bono JS. A phase I study of wild-type reovirus, which selectively replicates in cells expressing activated Ras, administered intravenously to patients with advanced cancer. Eur J Cancer 4(12S), 2006. PMID: None.
162. de Bono JS, Boss D, Fong P, Roelvink M, Yap TA, Tutt A, O’Connor M, Schellens J, Kaye S. Phase I evaluation of an inhibitor of PARP, KU-0059436 in patients with advanced tumours. Eur J Cancer 4(12S), 2006. PMID: None.
163. Patel A, Williams D, O’Donoghue M, Paulsen A, Hare A, Yap TA, Elkin S, Kon OM. Comparison of two tuberculosis clinic services. Thorax 59(2):92 [P162], 2004. PMID: None.
164. Lee B, Neighbour H, Yap TA, Kon OM, Wright A, Elkin S. Baseline survey of practice in diagnosis and staging of carcinoma of the bronchus. Thorax 59(2):19 [S57], 2004. PMID: None.

Book Chapters

1. Salguero, C, Brown, C, Robinson, HM, Smith, GC, Yap, TA. Targeting ATR in Cancer Medicine, 239-283, 2023.
2. Barata P, Yap TA. None. In: Development of molecularly targeted agents in early phase clinical trials. None. Springer, 2020.
3. Yap TA, de Bono JS. AKT. In: Cancer Therapeutic Targets. None. Springer, 1-10, 2016.
4. Mateo J, Yap TA, de Bono JS. PARP Inhibitors. In: Management of Castration Resistant Prostate Cancer. None. Humana Press, 253-264, 2014.
5. Yap TA, Popat S. Emerging targets and new agents in lung cancer. In: Thoracic Tumours: Essentials for Clinicians. None. ESMO Press, 73-76, 2014.
6. Mateo J, Ong M, Yap TA, de Bono JS. Opportunities And Pitfalls Of Targeted Therapeutic Combinations In Solid Tumors. In: Am Soc Clin Oncol Educ Book. None. None, 670-4, 2012.
7. Yap TA, Drew Y, Shanley S. Biology of BRCA1 and BRCA2 genes and implications for cancer management. In: The Translation of Biology to the Clinic. None. RCOG Press, 57-74, 2011.
8. Drew Y, Yap TA, Kaye SB. The future of PARP inhibitors in the treatment of cancer. In: Gynaecological Cancers: Biology and Therapeutics. None. RCOG Press, 83-98, 2011.
9. Yap TA, Kaye SB, Ashworth A, Tutt A. Tumour-specific synthetic lethality: targeting BRCA dysfunction in ovarian cancer. In: Emerging Therapeutic Targets in Ovarian Cancer. None. Springer-Verlag, 109-132, 2010.
10. Yap TA, Sarker D, Kaye SB, de Bono JS. Functional imaging: Clinical applications in molecular targeted therapy. In: Husband and Reznek’s Imaging in Oncology. 3rd. Informa Healthcare, 1366-1383, 2009.
11. Yap TA, Molife LR, de Bono JS. CDK inhibitors as anti-cancer agents. In: Checkpoint Responses in Cancer Therapy: Cancer Drug Discovery & Development. None. Humana Press, 135-162, 2008.
12. Ivy SP, Yap TA. None. In: Designing Trials for Drug Combinations. None. None.

Books (edited and written)

1. Yap TA, Rodon J, Hong DS. Phase I Oncology Trials. Ed(s) None. Springer, 2020.

Letters to the Editor

1. Almanza-Huante E, Bataller A, Urrutia S, Gener-Ricos G, Briski RE, Kanagal-Shamanna R, Lu KH, Westin SN, Yap TA, Takahashi K, Ravandi F, Alvarado Y, Kadia T, Sasaki K, Kantarjian HM, Garcia-Manero G. Outcomes of patients with therapy-related myeloid neoplasms after treatment with poly(ADP-ribose) polymerase proteins inhibitors for solid tumours. Br J Haematol 201: e25-e29, 2023.
2. Thein KZ, Piha-Paul SA, Tsimberidou A, Karp DD, Janku F, Fu S, Subbiah V, Hong DS, Yap TA, Shah J, Milton DR, McQuinn L, Gong J, Tran Y, Carter BW, Colen R, Meric-Bernstam F, Naing A. Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors. Exp Hematol Oncol 10: 59, 2021.
3. Janku F, Hess KR, Yap TA. Moving Precision Oncology Forward Amid Myths and Misconceptions. JAMA Oncol 4: 1788-1789, 2018.
4. Yap TA, Banerji U, de Bono JS, Workman P. Biopsy-Derived Biomarkers in Phase I Trials: Building Confidence in Drug Development. J Clin Oncol 34: 2431-2, 2016.
5. Lim JS, Turner NC, Yap TA. CDK4/6 Inhibitors: Promising Opportunities beyond Breast Cancer. Cancer Discov 6: 697-9, 2016.